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IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ESTROGEN 
RESPONSE ELEMENTS IN THE HUMAN HERPESVIRUS 8 GENOME 
Patrick R Shea, Ph.D. 
University of Pittsburgh, 2008
 
Interaction between viral infection and host genetic susceptibility has increasingly 
become recognized as an important factor in the etiology of human cancer.  Epidemiologic 
studies suggest that prostate cancer is a complex disease involving host genetic factors and 
environmental exposures that modify risk.  Here we report a novel interaction between infection 
with human herpesvirus 8 (HHV8) and the human estrogen receptor alpha XbaI polymorphism 
which is associated with an increased risk of prostate cancer (p=0.032; OR=3.10 95%CI (1.42-
6.77)) in an Afrocaribbean population from Tobago.  HHV-8 is the causative agent in Kaposi’s 
sarcoma (KS).  Despite similar HHV-8 seroprevalences, KS lesions are much less common in 
females, suggesting that sex hormones influence KS pathology.  The estrogen receptor (ER) is a 
ligand-dependant transcription factor that mediates the genomic effects of hormone signaling.  
Because of the suggested role of sex hormones in KS development and prostate cancer risk, we 
hypothesized that some HHV-8 genes might be activated by ER.  We computationally scanned 
the HHV-8 genome for estrogen response elements (EREs). Our analysis identified high scoring 
EREs in the promoter regions of several genes in the HHV-8 genome, including the regulatory 
gene K8.  Binding of ERs to HHV-8 EREs was confirmed by electrophoretic mobility shift assay 
and ELISA.  To demonstrate that HHV-8 EREs were functional, promoter regions were cloned 
into reporter plasmids and luciferase expression measured with and without estradiol.  Our 
results demonstrated increased reporter transcription in response to estrogens in cells expressing 
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ERα.  Further, we analyzed other gammaherpesviruses and identified several conserved EREs, 
including high-scoring EREs in the promoter of the EBV homolog of K8.  These results indicate 
that estrogen may influence transcription from the HHV-8 genome, outside of the normal viral 
transcription pathway.   Our findings may help to explain the differential risk of KS and could 
represent an important regulatory pathway in other gammaherpesviruses.  Prostate cancer and 
KS present a tremendous burden on public health, not only in the US, but worldwide.  Insights 
into the pathogenesis of these diseases may help us to understand their basic biology and provide 
potential screening and therapeutic targets   
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1.0  INTRODUCTION 
Virtually all organisms on Earth are subject to the constant threat of pathogen infection 
and have been locked in a figurative arms race with pathogens for millennia.   Many of 
these pathogens spend the majority of their lifecycle inside the host where they are 
constantly interacting with the host microenvironment, whether in the form of evading 
host defense mechanisms, pirating genes, or utilizing host cellular processes to 
accomplish their own goals.  As we begin to understand more about the interplay 
between host and pathogen, it becomes clear that these interactions occur on multiple 
levels, from simple protein-protein interactions, to the manipulation of gene expression, 
to the very shaping of the host’s genome through selective forces.  Genetic variation that 
influences these integrated biochemical and signaling pathways is likely to contribute to 
individual differences in disease phenotypes associated with pathogen infection.  In order 
to understand human disease phenotypes resulting from pathogens, we must unravel these 
complex relationships. 
Prostate cancer is a prototypical complex disease, with a variety of interacting 
factors, including both genetic and environmental causes.  Here we describe the 
identification of a novel interaction between a genetic variant in the human estrogen 
receptor alpha gene that when present in men from Tobago infected with human 
herpesvirus 8 (HHV8), significantly increases the risk of prostate cancer.  We further 
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attempt to characterize this novel interaction and in doing so potentially provide insight 
into the etiology of Kaposi’s sarcoma, another disease associated with HHV8 infection. 
1.1 TOBAGO POPULATION 
Tobago is a small Caribbean island located approximately 11 miles off the coast of 
Venezuela.  Tobago, along with its sister island Trinidad, comprise the nation of Trinidad 
and Tobago.  A national census conducted in 2000 estimated the population of Tobago to 
be 54,084 (1).  Despite their relatively close proximity, Trinidad and Tobago have very 
distinct population ancestries, largely due to their unique histories as slave trading 
colonies.  Recent estimates of genetic ancestry have found the Tobago population to be of 
approximately 94.0% African, 4.6% European and 1.4% Native American origin (2).  
This fairly homogeneous composition makes the Tobago population an ideal population 
for genetic studies of disease that may otherwise suffer from confounding due to 
underlying genetic admixture and population substructure.  Tobago is also an interesting 
population for scientific study because it has one of the highest rates of prostate cancer in 
the world, with a screening-detected prevalence of 14 per 100 men, ages 50-79, screened 
(3).   
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1.2 PROSTATE CANCER 
1.2.1 Prostate cancer background 
Prostate cancer is the most commonly diagnosed non-skin related cancer among men 
living in the United States and has the second highest mortality rate of all cancers (4).  
Therefore prostate cancer represents a tremendous burden on public health in the United 
States as well as worldwide. 
Prostate cancer is considered to be a complex disorder with multiple causative 
factors, including both genetic and environmental influences.  Familial aggregation of 
prostate cancer was first reported by Morganti et al who observed that prostate cancer 
patients reported a higher family history of prostate cancer than did patients hospitalized 
with other disorders (5).  Additional formal family studies of men diagnosed with 
prostate cancer confirmed these observations and found an elevated risk among related 
family members (6,7).  Further, studies of twins have shown that identical twins have an 
increased level of concordance than fraternal twins or other siblings, suggesting that 
heritable genetic predisposing factors contribute to prostate cancer (8,9).  Estimates of 
heritability indicate that approximately 40% of prostate cancer risk can be attributed to 
these genes (8,10,11).  
Prostate cancer also displays significant variability in incidence depending on 
racial ancestry, with African Americans at almost twice the risk of Caucasians, while 
prostate cancer is less common in Asians and Asian Americans (Table 1). 
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Table 1. SEER Prostate Cancer Statistics 2000-2004 
 Incidence  Mortality 
US Total  168 27.9 
Blacks 255.5 62.3 
Whites 161.4 25.6 
Asians/Pacific Islanders 96.5 11.3 
 
Incidence and mortality statistics are shown per 100,000 individuals  
 
Differing environmental factors may contribute to risk, as illustrated by the 
increased risk in prostate cancer in Asians who immigrate to the US.  However the 
incidence of prostate cancer in these immigrants remains similar to that of their ancestral 
homeland and never reaches levels observed in other groups, suggesting the existence of 
shared racial genetic predisposition factors (12). 
1.2.2 Role of hormones in prostate cancer 
The growth and development of the prostate gland has been found to be heavily 
influenced by steroid hormones.  The role of hormones in the prostate was first noted 
when it was observed that castration of males had a beneficial effect on prostate cancer 
(13).  Androgens have long been known to control proliferation of prostate tissue and 
androgen deprivation continues to be one of the primary treatments for cancer of the 
prostate.  Androgen deprivation results in a significant atrophy of the prostate gland, 
primarily affecting the epithelial cells of the prostate lumen (14).  Despite this clear 
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influence on prostate growth, serum levels of androgens does not appear to be associated 
with prostate cancer risk (15). 
More recently, estrogens have been shown to have an important influence on the 
early developmental morphology of the prostate.  In animal models, proper levels of 
circulating estrogens have been found to be important for gland development. Mice 
exposed to abnormally high levels of estrogens during prostate gland development were 
observed to have malformations of the prostate (16) and were predisposed to 
precancerous lesions in the prostate (17).   Prenatal exposure to estrogens has also been 
reported to result in an effect known as “imprinting” in which the prostate becomes 
sensitized to estrogens and shows reduced sensitivity to androgens (18).   This 
developmental estrogenization showed a distinct lobe-specific effect on androgen 
receptor expression (18).   Despite these findings, numerous studies have failed to find 
any correlation between circulating hormone levels in men and risk of prostate cancer 
(19).   
1.2.3 Estrogens 
1.2.3.1 Role of estrogens 
Despite the general notion that estrogens are a female sex-hormone, both men and 
women have detectable levels of estrogens in their circulation.  Estrogens are 
biosynthesized from cholesterol in a process known as steroidogenesis.  In this process, 
cholesterol is metabolized into androgenic compounds which then undergo aromatization 
into estrogens.  The three most significant of these estrogenic compounds are estrone, 
estradiol, and estriol (figure 1).    
  
Figure 1. Structure of the Major Biological Estrogens 
Derived from Jordan et al (20) 
 
Estradiol can be directly synthesized through the aromatization of testosterone or through 
an indirect pathway in which androstenedione is first aromatized to estrone which is then 
converted to estradiol by 17β-hydroxysteroid dehydrogenase.   Estriol is synthesized by 
the direct metabolism of estradiol or by conversion of estrone to hydroxyestrone which is 
then converted to estriol  (21).   
Estradiol is the primary estrogenic compound in premenopausal women and is the 
most potent estrogen of the major estrogens synthesized by the body (22).  After 
menopause the ratio of estrogens changes dramatically and estrone predominates.  In 
men, estrogens are created through aromatization of androgens in peripheral tissue and in 
the testes (23).  Total serum levels of estradiol and estrone increase as men age due to 
increasing rates of aromatization (24), with a corresponding decline in testosterone level 
(23).  This results in a marked change in the androgen:estrogen ratio.  Further, levels of 
estrogen are known to increase within the prostate gland as men age (25). 
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1.2.3.2 Actions of estrogens 
Estrogens carry out their biological effects through three primary mechanisms.  Each of 
these mechanisms utilizes a protein receptor molecule called the estrogen receptor which 
specifically recognizes and binds estrogenic compounds.  In the first mechanism, 
estrogens bind to estrogen receptors located in the nucleus which undergo a 
conformational change which allows them to bind to specific recognition sequences in 
the genome (26).  The bound estrogen receptor then activates nearby proteins involved in 
RNA transcription or recruits other activator or repressor proteins to the transcription 
start site.  An alternate form of this mechanism, called tethering, involves an indirect 
binding to DNA wherein the estrogen receptor is bound by protein-protein interaction to 
another transcription factor that is directly bound to a recognition site.  The estrogen 
receptor has been observed to tether to SP1 and AP1 transcription factors in the 
promoters of certain estrogen-responsive genes that do not contain estrogen receptor 
binding sequences (27-29).  The third method of estrogen signaling involves a splice 
variant of the estrogen receptor which localizes to the cell membrane.  This method of 
signaling is much more rapid and involves signaling through the nitric oxide synthase 
pathway (30).   
1.2.3.3 Estrogen receptors 
There are two forms of the estrogen receptor transcribed from distinct loci on 
chromosome 6 and chromosome 14, known as the estrogen receptor α (ESR1) and β 
(ESR2), respectively.  These two receptors share significant homology and appear to 
have arisen from an ancestral duplication event based on gene synteny in these regions 
(31).  Both receptors have a similar structural organization, including an N-terminal 
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activation function (AF-1), DNA binding zinc-finger region, hinge region, ligand binding 
domain, and C-terminal activation function region (AF-2) (32).  The AF-2 region is the 
domain responsible carrying out transcriptional activation in response to estrogens, while 
the AF-1 region provides a low-level of transcriptional activation that is ligand-
independent (32). 
1.2.3.4 Ligand binding of estrogen receptors 
The estrogen receptors bind a variety of estrogens and estrogen-like molecules with 
varying affinity.  The two receptors can also have differential responses to estrogens as 
well, with some compounds acting as transcriptional activators when bound to one 
receptor, but acting as an antagonist when bound to the other.  To further complicate 
matters, local tissue-specific co-regulators, such as members of the SRC family, SMRT, 
and the TRAP/DRIP protein complex (26), can also modulate the effect of a receptor  
(33).   Binding of estrogens to the receptor occurs at the ligand-binding domain and 
results in a conformation change in the structure of the estrogen receptor protein (34).  
This conformational change influences how amino acid residues in the AF-2 region 
interact with nearby transcription factors and parts of the general transcription machinery 
(33).  Compounds which have an antagonisitic effect of the receptor can also act to 
inhibit dimerization of the receptor and can influence receptor half-life by causing the 
receptor to be targeted for ubiquitination and proteasomal degradation (35,36).  
1.2.3.5 Estrogen receptor transcription 
Transcription of both estrogen receptors is complex process, with each receptor having 
multiple transcription start sites in the 5’-region.  The promoter region of the alpha 
receptor has at least 8 different transcription start sites (37).  Transcription from these 
various start sites results in mRNA species with differing 5’-untranslated sequences with 
over 9 reported untranslated exons (37).  Similarly, the ERbeta 5’ region includes at least 
7 untranslated exons (38) (Figure 2) 
 
 
Figure 2. Map of the Estrogen Receptor Coding and Non-Coding Exons 
Reprinted with permissions from Hirata et al (38) 
 
The exact function of these untranslated exons is unknown, however they have 
been hypothesized to be involved in sub-cellular localization and have been reported to 
play a role in tissue specific expression (39).   Although the estrogen receptor mRNA 
species are exceptionally variable, the translated receptor proteins have a high degree of 
similarity (37).  Several isoforms of each receptor protein have been identified.  At least 2 
ERalpha proteins have been observed, including the full length 66kDa wildtype protein 
and a 46kDa receptor protein lacking 173 amino acids from the N-terminus.  The 46kDa 
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protein originates from an alternatively spliced mRNA lacking the first coding exon (1A) 
with translation occurring from an internal ATG start codon (40).   This receptor lacks the 
AF-1 domain and acts as a competitive inhibitor of AF-1 function of the wildtype 66kDa 
receptor.  However, the truncated receptor is still capable of binding ligands and can 
activate transcription from an estrogen-responsive promoter (40).  In endothelial cells, the 
46kDa ERalpha has been shown to localize at the plasma membrane where it plays a role 
in rapid non-genomic action of estrogens involving the eNOS pathway (30). 
The beta estrogen receptor is also expressed as several isoforms.  The full length 
receptor is the most common form, however 2 variants exist, named ERbeta-cx and 
ERbeta-ins (also known as ERB2).  The ERbeta-cx isoform is expressed as a mRNA 
containing an alternative 3’ exon which subsitutes the final 61 amino acids of the 
receptor, including portions of the ligand binding domain, with 26 unique amino acids 
(41).  The ERbeta-cx variant does not appear to bind estrogen ligands and acts as an 
inhibitor of wildtype ERalpha and ERbeta (41).  The ERbeta-ins isoform is derived from 
an alternatively spliced ERbeta transcript which contains an 18 amino acid insertion 
located in the ligand binding domain (42).    ERbeta-ins was found to be capable of 
binding estrogen ligands, however it was shown to have a 35-fold lower affinity for 
estradiol (42).  ERbeta-ins acts similarly as an inhibitor of the wildtype receptor isforms  
(43). 
1.2.3.6 Tissue-specific expression of estrogen receptors 
The estrogen receptors have distinct profiles of tissue-specific expression, which can vary 
greatly even within a single organ.  To some degree this variable expression can be traced 
to the different mode of action of the receptor within tissue where it is expressed.  An 
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example of this is the expression of the membrane-bound form of the alpha estrogen 
receptor in vascular endothelial cells which is responsible for the rapid signal 
transduction via the nitric oxide pathway in response to circulating estrogens (30).   
Another example of the tissue-specific expression of the estrogen receptors can be seen in 
the prostate gland.  The glandular epithelial cells which line the ducts of the prostate 
primarily express the beta estrogen receptor, while the prostatic stromal cells mainly 
express the alpha receptor (44,45).  
1.2.3.7 DNA binding 
It was known for some time that action of estrogens was carried out by binding to 
estrogen receptors. However, it wasn’t recognized for some time that the estrogen 
receptors acted by binding to specific DNA regulatory elements, until regions of DNA 
that bound estrogen receptor were discovered upstream of estrogen-responsive genes.    
Jost et al initially identified a segment of the chicken vitellogenin II gene which was able 
to bind estrogen receptor in vitro (46).  After the identification of several other regions 
capable of binding estrogen receptor and further fine mapping, a general consensus 
sequence was assembled from conserved regions in each of these sequences (47-49).  
This region was found to consist of a 13bp palindromic sequence of GGTCA-NNN-
TGACC composed of two 5bp half sites separated by a 3bp linker (47).   This regulatory 
element, known as an estrogen response element (ERE), was found to act as an enhancer 
which had the ability to have an effect on gene expression even when located up to 2.6kb 
from the transcription start site (TSS) (47).   Functional ERE sequences have been shown 
to be present in front of the TSS as well as inside coding regions and in 3’ regions of 
estrogen-responsive genes (50).   
 12
1.2.3.8 Computational modeling of estrogen response elements 
The ERE consensus sequence has been shown to be able to tolerate some degree of 
variability and certain positions in the palindrome have been shown to be more 
constrained than others.  As little as a single change can abolish DNA binding, however 
up to 2 deviations from the standard ERE consensus have been shown to be able to bind 
estrogen receptor and increase gene expression (51).  Any changes in the ERE are better 
tolerated if they are present in only one of the two half sites (52).  Deviations from the 
ERE consensus sequence can also be rescued by the presence of a purine immediately 
flanking the half site (51).  Additionally, the presence of AT-rich flanking sequence can 
increase how potent the response element can modify transcription (52).   However, it has 
been shown that the binding affinity of the receptor to an ERE does not linearly predict 
how well the bound receptor will modify transcriptional activity (53) and most estrogen 
responsive genes identified in the human genome do not have perfect ERE consensus 
sequences (54).   
The estrogen receptor protein has been shown to form a stable dimer which binds 
to the ERE sequences with each receptor monomer interacting with one of the ERE half-
sites (55).  This DNA-protein interaction occurs in the major groove of the DNA helix 
with the receptor protein making specific contacts between amino acids in the receptor 
zinc-finger and the exposed functional groups of the nucleotide bases (53) and both the 
alpha and beta estrogen receptors appear to interact with the same nucleotides of the ERE 
(56).  The presences of multiple ERE sequences upstream of a gene have been shown to 
have the ability to act in a synergistic manner and have been called estrogen response 
units or ERUs (57).   
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The extensive characterization and limited variability of the ERE sequence makes 
it well suited for computational modeling which can then be used to predict ERE sites in 
a novel DNA sequence.  Initially, modeling of the ERE sequence was done using IUPAC 
representation of nucleotide bases and has progressed to more robust computational 
methods.  Currently several computational methods are used to identify ERE sequences 
with 2 being the most commonly used.  The first method involves the use of a position-
specific scoring matrix (PSSM) to represent the probability of a particular nucleotide at 
each position in the ERE.  The PSSM is constructed by aligning a group of DNA 
sequences which are known to act as classical EREs.  The number of occurrences of a 
particular nucleotide base at each position are then totaled and entered into a scoring 
matrix.  These counts are then converted to probability values.  Searching for ERE 
sequences within a novel sequence is then done by scanning along the sequence using a 
sliding window the size of the ERE sequence.  For each iteration, the sequence within the 
window is then compared to the probability matrix and scored based on its similarity.  
The second methodology for modeling ERE sequences utilizes a decision tree to separate 
ERE-like sequences into two categories using two PSSMs.  The first PSSM is constructed 
using sequences present in front of genes shown to respond to estradiol and the anti-
estrogen faslodex (50).  This list was further refined by experimentally validating that 
these sequences bound ER protein using a microarray-based chromatin 
immunoprecipitation assay (ChIP-on-chip) (50).  The second PSSM represents ERE-like 
sequences which were not found to bind ER protein or “non-binding” sequences. one 
representing sequences experimentally validated to bind ER protein and modify 
transcription (50). A third method of computationally identifying ERE sequences, utilized 
in the DragonERE program, incorporates the use of a PSSM matrix and an artificial 
 14
neural network trained to differentiate between true ER binding sequences and non-
binding ERE-like sequences (58). 
1.2.3.9 Estrogen receptor variation 
Numerous genetic variants have been identified in the estrogen receptor alpha gene, 
including a large number of non-coding polymorphisms as well as several missense and 
non-sense mutations (Summary in Table 2).   
 
Table 2. Reported Estrogen Receptor Alpha Genetic Variation 
Location Change Rs Number
Promoter TA repeat rs3138774 
Exon 1 S10S rs2077647 
 S77G rs9340773 
 A87A rs746432 
 S118P n/a 
 Q146P rs17847065 
Exon 2 R157X n/a 
 S168T rs17847076 
 T168T rs9340802 
Exon 3 R243R rs4986934 
Exon 4 P325P rs1801132 
 V364E n/a 
Exon 5 L379L rs17847067 
Exon 6 C447A n/a 
Exon 8 K531R n/a 
 R548H n/a 
 A558A rs9341068 
 T563M n/a 
Table 2 Continued 
 A571A rs9341069 
 E587E rs34840398 
 T594T rs2228480 
Intron 1 -1505 A/G rs48070056 
 -1415 T/C rs9322331 
 -397 C/T rs2234693 
 -351 A/G rs9340799 
 GGGA repeat rs10692281 
 
Of these variants, several have been repeatedly associated with human disease.  In 
particular 2 polymorphisms located 397 and 351 bp upstream of exon 2 have been 
reported to be associated with a number of disorders including  breast cancer (59), bone 
mineral density (60), bone-fracture (61), osteoarthritis (62), heart-attack (63),  
cardiovascular disease (63), lung function (64), anxiety-related traits (65), and prostate 
cancer (66).  The PvuII polymorphism (rs2234693), a C->T transition located -397 from 
exon 2, has been shown to introduce a binding site for the c-myb transcription factor 
which when inserted into a reporter plasmid was shown to be responsive to c-myb 
expression (67).  While the XbaI polymorphism (rs9340799) has been associated with 
estrogen-related disease, the A->G transition (Figure 3) has not been shown to have any 
known effect on function. 
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 Figure 3. ESR1 Region with XbaI and PvuII Polymorphisms 
Adapted from Herrington et al (67) 
 
Variation that influences disease risk has been identified in the estrogen receptor 
beta as well.  A polymorphic CA dinucleotide repeat has been identified in intron 5 of the 
ESR2 gene and has been associated with several disorders, including systolic blood 
pressure (68), Alzheimers disease (69), osteoarthritis (70), and risk of hypospadias (71). 
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1.2.3.10 Linkage disequalibrium in the estrogen receptor alpha gene 
The human estrogen receptor alpha gene also displays an extensive amount of linkage 
disequalibrium (LD) in its 5’ region which can be a challenge to attempts to identify 
causal variation (72).    LD is defined as the non-random association of 2 or more alleles 
in a population (73).  LD generally arises when genetic variation occurs in a 
chromosomal region with limited recombination between the alleles (74).   These alleles 
are then transmitted on the same chromosomal segment until such time has passed as to 
allow recombination to occur between the alleles. A region of LD has been reported to 
encompass the region of intron 1 containing the XbaI and PvuII polymorphisms as well 
the TA dinucleotide repeat in the 5’ region (75) In Caucasians, this block of LD extends 
across a 41kb region of the ESR1 gene while in African populations, this large block of 
LD is broken down into several smaller fragments (Figure 4).  As a result, variants 
located within this region may be transmitted on a common haplotype background 
together with the causative allele, result in a spurious association between variants in 
other parts of the LD block and the disease. 
 
 Figure 4. HapMap Plot of Linkage Disequilbrium in ESR1 5'-Region 
Linkage disequalibrium for each marker pair is measured using D’.  For marker pairs with a log 
odds of less than 2.0, pairs with D’=1 are indicated in blue, D’>1 in white.  For marker pairs with a 
log odds of 2.0 or greater, pairs with D’=1 are shown in dark red, pairs with D’>1 are indicated in 
light red.  Image generated using the HapMap Project (76) genome browser and HapMap build 36. 
 18
 19
1.2.3.11 Viral etiology of prostate cancer 
Several epidemiologic studies of prostate cancer have suggested that an infectious agent 
may contribute to the risk of disease (77-79).  Several links between prostate cancer and 
risky sexual practices have been reported, including associations with several sexually 
transmitted diseases.  Hayes et al reported an increased risk of prostate cancer among 
men who had a history of gonorrhea or syphilis infection (80).  This risk was shown to 
increase with the lifetime number of infections and was reduced with long-term use of 
condoms. These results agree with that of Krain which reported that men with prostate 
cancer have significantly more occurrences of sexually transmitted disease (81).  
Gonorrhea and syphilis infection are generally regarded as sentinel diseases, therefore 
associations with these pathogens may simply be a surrogate indicator of other sexually 
transmitted diseases (80).  However, numerous studies have failed to find consistent 
associations between prostate cancer and other indicators of risky sexual behavior such as 
lifetime number of sexual partners (80) or HPV infection (82). 
Most studies of viral pathogens involved in prostate cancer have failed to 
consistently identify any particular pathogen associated with an increased risk of disease.  
However, a recent study of prostate cancer patients who carried two copies of a mutant 
RNASEL allele found the presence of a novel retrovirus called xenotropic murine 
leukemia virus (XMRV) in prostate tumor sections (83).  While it remains unclear if 
XMRV contributes directly to prostate cancer risk or is simply present due to reduced 
viral clearance by the mutant RNASEL enzyme, their finding certainly suggest a 
relationship between pathogen infection and prostate cancer in genetically susceptible 
men.   Several studies have failed to find any link between herpes simplex infection and 
prostate cancer (84,85), however, another member of the herpesvirus family has been 
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implicated in prostate cancer risk.  In a study of men from the island of Tobago, Hoffman 
et al reported that men who showed serological evidence of infection with human 
herpesvirus 8 (HHV8) had over twice the risk of prostate cancer (86).  HHV8 DNA has 
also been reported to be found in ejaculate of healthy Italian men as well as in urinary 
tract tissue, including in over 40% of prostate tissue sections (87), suggesting the virus is 
present in the male urogenital tract.  These findings were supported by the PCR 
identification of HHV8 DNA in the prostate gland of men with Kaposi’s sarcoma (KS) 
(88)   Further, Montgomery et al reported finding viral protein expression and increased 
levels of inflammation in prostate sections of HIV+ men who were seropositive for 
HHV8 (89).   While these studies intriguingly suggest a role for HHV8 in increasing the 
risk of prostate cancer, several studies have failed to find a serological association 
between HHV8 and prostate cancer risk (84,90).  However, these latter studies were 
conducted on populations living in diverse areas and the risk of prostate cancer risk may 
only be associated with HHV8 in genetically susceptible men in areas with high 
prevalence of HHV8 infection such as Italy, sub-Saharan Africa or Tobago. 
1.3 HUMAN HERPESVIRUS 8 
1.3.1 Background 
Human herpesvirus 8 (HHV8), also known as Kaposi’s sarcoma herpesvirus or KSHV, 
was first identified in 1994 by Moore and Chang using a representational difference 
analysis technique to extract novel viral DNA from the skin lesion of an HIV+ patient 
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with Kaposi’s sarcoma (91).  HHV8 has been identified as the causative agent in all 
forms of Kaposi’s sarcoma (KS) (92) and has been linked to several rare 
lymphoproliferative disorders (93,94).    HHV8 has a double-stranded DNA genome of 
over 165,000 nucleotides in length which is composed of a 145kb segment of unique 
sequence situated between G-C rich terminal repeat regions (95).  The viral genome is 
packaged in an icosahedral capsid with a final molecular weight of approximately 
300MDa.  The HHV8 genome contains approximately 90 predicted open reading frames 
(ORFs) (96,97).  Approximately half of these open reading frames belong to a core of 
evolutionarily conserved genes present in other herpesviruses (98).  Conservation of these 
core herpesvirus genes includes not only a high degree of protein sequence similarity, but 
also retained gene synteny (99).  
1.3.2 Phylogenetics of the gammaherpesviruses 
HHV8 is phylogenetically classified as a member of the gammaherpesvirus family of 
viruses.  The gammaherpesviruses are further classified into 2 subgroups, the 
lymphocryptovirus genus which includes Epstein-Barr virus and the rhadinovirus genus, 
of which HHV8 is a member (Figure 5). 
 
 Figure 5. Phylogenetic Tree of the Herpesviridae 
Reprinted with permission from Moore et al (99) 
 
The gammaherpesviruses are known to infect a diverse range of mammalian 
hosts, including sheep, pigs, horses, wildebeests, and a variety of primates species, 
including both New and Old world monkeys and man (100).  The gammaherpesviruses 
were originally characterized based on their ability to infect lymphocytes, induce 
lymphoproliferation in immunosuppressed hosts, and by comparison of their DNA 
polymerase gene sequences.  However, the recent availability of full genome sequences 
has aided their phylogenetic classification based on overall sequence conservation.  
Currently 12 members of the gammaherpesvirus family have fully annotated reference 
genome sequences available through the NCBI database (Table 3). 
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Table 3. List of Gammaherpesviruses with Full Genome Sequences Available at NCBI 
Virus Name Abbreviation Host RefSeq Accession 
Human herpesvirus 8 HHV8 Human NC_003409 
Human herpesvirus 4 EBV Human NC_007605 
Cercopithecine herpesvirus 17 RRV Rhesus monkey NC_003401 
Murid herpesvirus 4 MHV68 Mouse NC_001826 
Alcelaphine herpesvirus 1 AlHV1 Wildebeest NC_002531 
Bovine herpesvirus 4 BHV4 Cow NC_002665 
Callitrichine herpesvirus 3 CalHV3 Common marmoset NC_004367 
Cercopithecine herpesvirus 15 RLV Rhesus monkey NC_006146 
Ateline herpesvirus 3 HVA Spider monkey NC_001987 
Ovine herpesvirus 2 OHV2 Sheep NC_007646 
Equid herpesvirus 2 EHV2 Horse NC_001650 
Saimiriine herpesvirus 2 HVS Squirrel monkey NC_001350 
 
 
Of these, 9 belong to the rhadinovirus genus while the remaining 3 members are 
lymphocryptoviruses.  Virtually all members of the gammaherpesvirus family have been 
shown to induce cancer in their natural or foreign hosts.  Most induce a variety of 
lymphoproliferative disorders of B and T-cells, as well as endothelial lesions similar to 
KS. For example, infection of rhesus macaques with RRV has been reported to induce 
lymphoproliferation resembling multicentric Castleman’s disease (101), follicular 
hyperplasia and arteriopathy (102) similar to that observed in MHV68 and AHV1.  
Herpesvirus saimiri has been shown to induce T-cell lymphomas as well (103). 
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1.3.3 Viral lifecycle 
As with most members of the Herpesviridae, HHV8 has a biphasic lifecycle, consisting 
of latent and lytic phases.  In the latent or non-productive phase, the virus is not actively 
producing viral progeny and only a minor subset of genes is expressed (95).  These genes 
play various functional roles, including tethering the viral genome to host chromatin, 
avoiding immune surveillance, and interacting with the host cell cycle.   
In the lytic phase, the viral genome is replicated and packaged into viral capsids, 
resulting in the production of infectious progeny (95).  Genes expressed during the lytic 
phase are expressed in a temporal manner by function.  At the beginning of a lytic phase, 
an initial set of viral regulatory genes involved in transcriptional activation are expressed.  
These genes are known as the immediate-early genes (104).  The next sets of genes to be 
transcribed are known as the early genes.  These genes are involved in preparing the host 
cell for DNA replication, large scale protein synthesis and immune evasion (95).  
Following expression of the early genes, replication of the viral genome takes place.  The 
final set of genes expressed by the virus is known as the late genes and are primarily 
structural genes that compose the viral capsid (95).  Following expression of these genes, 
the viral capsid is assembled and the viral genome is packaged inside.  A group of 
proteins are attached to the capsid to form what is known as the tegument (95).  Finally, 
the virus capsid buds through the host membrane and is covered in a membrane coat, 
resulting in a mature viral particle (95). 
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1.3.4 HHV8 transmission 
Transmission of HHV8 is believed to differ significantly depending on geographic 
location and the level of individuals infected in the population.  In the US where levels of 
HHV8 infection are low, the virus is primarily transmitted as a sexually transmitted 
disease (105).  Homosexual men are particularly at risk (106), however the virus has been 
observed to be transmitted through heterosexual populations as well (95,107).  In 
contrast, in areas affected by endemic KS where much higher rates of HHV8 infection 
are present, HHV8 transmission has been observed in young children and generally 
believed to be passed from parent to offspring and horizontally among infected children 
(108,109).  Several rare cases of vertical transmission have been reported in which young 
children have viral DNA present less than 24 hours after birth (110). 
1.3.5 Rates of HHV8 infection 
Globally, the estimates of HHV8 infection vary dramatically by region.  In the United 
States and northern Europe serological studies have estimated the rate of HHV8 infection 
to be approximately 1-7% (95).  In areas of the Mediterranean, such as Italy, the 
prevalence of infection has been shown to vary from 7-25%, following a gradient 
increasing from north to south (111) with dramatically higher rates in Sardinia and Sicily 
of approximately 35% (112).  In areas of sub-Saharan Africa where KS in endemic, 
roughly 30-60% of the population shows serological evidence of infection with HHV8 
(95).   
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1.3.6 HHV8 clades 
The HHV8 genome shows some degree of diversity from region to region and has been 
divided into several distinct subtypes and clades.  These subtypes are defined by genetic 
differences in a hypervariable region of the genome containing the ORF K1 gene (113).  
The amino acid sequence of the K1 gene varies between 30 and 60% in its N-terminal 
region and allows the virus isolates to be categorized into 5 groups: A, B, C, D and E 
(114,115).  In North America and Europe, the A and C groups have been found to be the 
predominant form.  In sub-Saharan Africa, the B group predominates, while in Asia the D 
group is the most common isolate (116).  In South America the B and C subtypes are 
commonly found, while the E subtype has been shown to be present in indigenous 
populations (115) (Figure 6).  HHV8 also is found as 2 distinct allelic variants that have 
been postulated to arise due to a recombination event with the ancestral herpesvirus (95).  
These variants, named P (prototype) and M (minority), differ in sequence at the right-
hand portion of the genome (95).  Despite this diversity, no correlation between clinical 
symptoms or disease severity and virus clade/subtype has been found (117). 
 
 Figure 6. HHV8 Subtype Global Distribution 
Derived from Boshoff et al (117) 
1.3.7 HHV8 oncogenes 
HHV8 genome has been shown to carry a comparatively large number of genes pirated 
from the host genome, including several which may function as oncogenes.  Of these 
genes, several appear to mimic the regulatory activity of the host gene and often are 
unresponsive to host feedback mechanisms.  The first open reading frame in the HHV8 
genome encodes the K1 gene, a transmembrane glycoprotein that has a constitutively 
active ITAM domain (118,119).  Expression of K1 has been shown to be able to 
transform mouse fibroblasts which are capable of forming tumors in nude mice (120).  
The K15 gene has also been shown to have oncogenic potential.  K15 is spliced to form 
several unique proteins which contain between 4 and 12 transmembrane-spanning 
domains with a cytoplasmic tail that contains SH2 and SH3 binding motifs (95).  
Expression of K15 has been shown to interfere with B-cell receptor (BCR) signaling 
(121).  The Kaposin gene is expressed during both latent and lytic phases and is 
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expressed as 3 different protein isoforms (122). The smallest of these isoforms, KaposinA 
has been shown to be able to transform mouse fibroblast cells which can also form 
tumors when implanted in nude mice (123).  Lastly, the ORF 74 gene encodes a viral G-
protein coupled receptor with homology to the human IL-8 receptor (124).  The vGPCR 
protein contains a 7-transmembrane spanning region and has been shown to be capable of 
binding a variety of host signaling molecules, including both CC and CXC chemokines 
(125).  However, unlike the host IL-8 receptor which is response to negative feedback, 
the vGPCR is constitutively active (125).  vGPCR expression has been shown to be 
capable of inducing morphological changes and tumor formation in rat kidney and NIH 
3T3 cells (126), and can immortalize endothelial cells (127).  These vGPCR-transformed 
cells have been shown to express several angiogenic proteins including VEGF, VEGFR-2 
and VEGFR-3 (126-128), which have the potential to provide a highly angiogenic 
environment for nascent prostatic tumors.  While these genes have a clear oncogenic 
potential, they have only been observed to be expressed during the lytic phase of 
infection.  Therefore it is unclear how these genes might contribute to tumor formation 
and paracrine effects have been proposed as one possible mechanism (126). 
1.3.8 Lymphoproliferative disorders associated with HHV8 
While HHV8 was originally identified as the pathogen responsible for Kaposi’s sarcoma, 
it has been implicated in several other human lymphoproliferative disorders as well.  One 
of these disorders is a rare primary effusion lymphoma (PEL) that is characterized by a 
malignant effusion occurring within the visceral cavity (117).  The malignant cells in this 
disorder are derived from preterminally differentiated B-cells (129) and show the 
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presence of a relatively high copy number of HHV8 DNA (117).  HHV8 has also been 
associated with another lymphoproliferative disorder known as multicentric Castleman’s 
disease (MCD).  HHV8 is known to cause a specific subset of MCD affecting HIV 
positive patients and approximately 50% of MCD in non-HIV patients (130,131).  This 
form of MCD is characterized by the presence of immature B-cell precursors known as 
plasmablasts.  This unique form of MCD has been designated as “plasma-cell variant 
MCD” (132). 
1.3.9 Kaposi’s sarcoma 
KS is the disorder for which HHV8 is most classically known.   The disorder was first 
identified by the Hungarian dermatologist Moritz Kaposi in 1872 (133).   KS presents 
clinically as a highly vascularized skin lesion.  In the initial stage of KS, called the patch 
stage, the KS lesion develops in proximity to normal blood vessels as groups of irregular 
spaces lined with endothelial cells with the presence of an inflammatory cell infiltrate 
(117).    KS then progresses to the plaque stage, characterized by the presence of spindle-
shaped cells of endothelial origin (95).  The KS lesion takes the form of slit-like channels 
that contain erythrocytes (117).  In the final or nodular stage, the KS lesion is composed 
of sheets of spindle cells (95). 
Four epidemiologic forms of KS have been characterized: classic, endemic, 
iatrogenic, and HIV-associated KS.   Classic KS is generally associated with elderly men, 
particularly of Italian, Greek, and Ashkenazi Jewish ancestry.  The classic form of KS 
has an average age of onset of approximately 60 years of age (134).  The endemic form 
of KS is found in sub-Saharan African, with the highest prevalence occurring in the 
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equatorial region (134).  Endemic KS predates the emergence of HIV in Africa (135) and 
has a much earlier age of onset than classic KS (136).  Infection of children is also 
observed in endemic KS and transmission from infected parent to child is believed to be 
the primary mechanism of transmission (108).  Iatrogenic or transplant associated KS, 
occurs post-operatively in organ transplant patients taking immunosuppressant drugs.  
The recipient of an organ transplant is at a much higher risk of developing KS than is the 
organ donor.  The development of KS has been shown to be linked to the use of immune 
suppressive drugs that prevent rejection of the transplanted organ (137,138).  In most 
cases of iatrogenic KS, the patient was previously infected with HHV8 rather than 
contracting the infection through the transplant procedure itself (139).  The most recently 
identified form of KS is HIV-associated KS.  This form occurs predominately in 
homosexual men infected with HIV, but is also observed at lower rates in HIV positive 
intravenous drug users (140).    
One of the most striking observations in the epidemiology of KS is its profound 
sex bias.  While men and women show similar rates of infection with HHV8, men are at 
significantly higher risk of developing KS.  In the US, men develop KS 13 times more 
frequently than women (4).  In areas affected by endemic KS, such as Uganda, estimates 
of KS prevalence have found it to be 15 times more common in men (134).  These 
differences in KS prevalence cannot be explained by differences in the rate of HIV 
infection and even in regions with similar rates of HHV8 and HIV infection, men are at a 
much higher risk of developing AIDS-KS (141).  This striking sex bias suggests a 
possible role for sex hormones in the etiology of KS.    
Several studies have linked the onset of KS progression with a marked increase in 
HHV8 viral load.  Whitby et al first observed that the presence of detectable levels of 
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viral DNA in bloodstream was a predictor of patients with an increased risk of 
developing KS lesions (142).  Further, it was reported that increasing viral load levels are 
correlated with the onset of KS (143,144).   
1.4 SUMMARY 
Epidemiologic studies have shown that prostate cancer clearly has a complex etiology, 
with both genetic and environmental risk factors.  The biology of prostate development 
and regulation has been shown to be strongly regulated by both androgens and estrogens.  
However, the involvement of the androgen and estrogen receptor in prostate cancer 
remains unclear.  Pathogen infection has similarly been implicated in increasing risk of 
prostate cancer. In particular, sexually transmitted diseases have frequently been 
investigated as causative agents.  Human herpesvirus 8 has recently been associated with 
an increased risk of prostate cancer in a population of Afro-Caribbean men from the 
island of Tobago (3).  As previously mentioned, despite similar HHV8 seroprevalences, 
men are at a much higher risk of developing KS than women, suggesting that hormonal 
factors may be important in KS pathology.  HHV8 has been shown to present in the 
prostate (89,145) and is known to encode several genes with oncogenic potential.  
Increased expression of HHV8 oncogenes mediated by the androgen and estrogen 
receptor may represent a novel causative mechanism in prostate cancer and Kaposi’s 
sarcoma.  Here we investigate the role of the androgen and estrogen receptors in HHV8 
biology and explore the implications of HHV8-hormone interaction in the etiologies of 
KS and prostate cancer. 
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2.0  HYPOTHESIS AND SPECIFIC AIMS 
2.1 HYPOTHESIS 
We have identified a statistical interaction between estrogen receptor alpha (ESR1) 
rs2234693 genotype and infection with human herpesvirus 8 (HHV8) that results in an 
increased risk of prostate cancer in Afrocaribbean men from Tobago.  HHV-8 has also 
been identified as the causative agent in all forms of Kaposi’s sarcoma (KS).  Despite 
similar HHV-8 seroprevalences in men and women, men are at a much higher risk of KS, 
suggesting sex hormones influence KS pathology.  The estrogen receptor (ER) is a 
ligand-dependant transcription factor that mediates the genomic effects of estrogen 
signaling. Here we propose a direct model of interaction between estrogens and human 
herpesvirus 8.  Specifically, this interaction involves estrogen response elements in the 
HHV8 genome that modify HHV8 gene transcription in response to estrogens.  These 
estrogen-mediated changes in transcription are responsible for the lower incidence of KS 
in women and may contribute to the observed increase in prostate cancer risk. 
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2.2 SPECIFIC AIMS 
1) To identify estrogen response element (ERE) sequences in the HHV8 genome by 
performing: 
a) a computational search of the HHV8 NCBI reference genome 
sequence for regions resembling the estrogen receptor consensus 
DNA binding sequence. 
b) Gel-shift assays to show that sequences identified computationally 
are capable of binding human estrogen receptor proteins. 
 
2) To experimentally validate whether candidate ERE sequences in the HHV8 
genome can act as function estrogen response elements, using: 
a) use luciferase reporter assays to show in vitro that HHV8 genes 
with ERE sequences in their promoter region are responsive to 
estrogen treatment and 
b) show that estrogens are able to modify target gene transcription in 
the context of the virus. 
 
3) To determine whether candidate ERE sequences found in the HHV8 genome 
sequence are conserved in the upstream regions of homologous genes found in 
other members of the gammaherpesvirus family. 
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3.0  RESEARCH DESIGN AND METHODS 
3.1 STUDY POPULATION 
Men ages 40-79 were recruited by word of mouth, informed by heath care workers, 
private physicians, posters, flyers, public service announcements, and public 
presentations by physicians from Trinidad and the US.  Over 60% of the eligible men in 
Tobago participated in the study.  Eligible men were screened by digital rectal exam 
(DRE) and prostate specific antigen (PSA) testing.  A 15ml sample of peripheral blood 
was collected prior to DRE and frozen at -20°C.  PSA levels were analyzed at the 
University of Pittsburgh Central Pathology Laboratory using automated Microparticle 
Enzyme Immunoassay (Abbot Ax-SYM PSA assay).   Systematic DREs were performed 
by a physician trained according to a standardized study protocol.    Individuals with 
abnormal DRE results or elevated PSA (≥ 4.0ng/ml) underwent trans-rectal, ultrasound 
guided biopsies.  A total of 405 men were diagnosed with prostate cancer and were 
designated as cases while 2685 men with normal PSA levels and normal or slightly 
abnormal DRE results were used as controls.  Approval for research of human subjects 
was obtained from the University of Pittsburgh Institutional Review Board (available in 
Appendix A) and the Tobago Ministry of Health. 
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3.2 DNA ISOLATION AND GENOTYPING ANALYSIS 
Genomic DNA was obtained from residual blood clots using the QIAgen Blood midi 
DNA kit according to the manufacturer’s instructions and stored at +4°C.  The CAG 
repeat in exon1 of the androgen receptor gene was genotyped by PCR amplification using 
TET, FAM, or HEX fluorescently labeled primers (designated ARA) in table 4, amplified 
using 30 cycles of the following conditions:  95°C for 30 seconds, 60.2°C for 30 seconds, 
72°C for 30 seconds, followed by a 7 minute extension at 72°C.  Amplification products 
were then run on a 7% polyacrylamide gel using an ABI 377 fluorescence DNA 
sequencer (Applied Biosystems) along with the GeneScan 500 ROX ladder (Applied 
Biosystems).  Allele sizes were determined by comparison with internal standards with 
repeat lengths previously determined by direct DNA sequencing.   
 
Table 4. PCR Primers Used For Estrogen and Androgen Receptor Genotyping 
Primer Name Sequence 
ARA-F 5’-ACC-GAG-GAG-CTT-TCC-AGA-AT-3’ 
ARA-R1 5’-AGA-ACC-ATC-CTC-ACC-CTG-CT-3’ 
ARA-R2 5’-CTG-TGA-AGG-TTG-CTG-TTC-CTC-3’ 
ARA-R3 5’-CAG-CTG-AGT-CAT-CCT-CGT-CCG-3’ 
ER-F 5’-ATC-CAG-GGT-TAT-GTG-GCA-ATG-AC -3’ 
ER-R 5’-ACC-CTG-GCG-TCG-ATT-ATC-TGA-3’ 
 
The estrogen receptor alpha PvuII and XbaI polymorphisms (rs9340799 and 
rs2234693) were assayed by PCR-RFLP analysis.   PCR amplification was performed 
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using the 0.75 ul of 20uM primers ER-F and ER-R in table 4 in a reaction volume of 50ul 
(28.8ul H20, 8.0ul of 1.25mM dNTP mix, 5.0ul 10x PCR Buffer (Gibco), 1.5 ul of 50uM 
MgCl2, 0.3ul of 5U/ul Taq polymerase).  Amplification was performed using 30 cycles of 
95°C for 30 seconds, 56.8°C for 30 seconds, 72°C for 30 seconds followed by a 10 
minute extension at 72°C in a MJ Research thermocycler.  Amplification products were 
then digested overnight at 37°C using XbaI or PvuII restriction endonuclease (NEB).  
XbaI digestion was performed using 15ul of PCR amplification product, 2.55ul H20, 
2.0ul 10x NEB Buffer #2, 0.2ul bovine serum albumin, and 0.25ul 20U/ul XbaI enzyme. 
PvuII digestions were performed using 15ul of PCR amplification product, 2.5ul H20, 
2.0ul 10x NEB buffer #2, and 0.5ul of 10U/ul PvuII enzyme. The restriction digest 
products were then separated by performing gel electrophoresis at 100V on a 2% agarose 
gel, stained with 5ug/100ml ethidium bromide.  Fragment sizes were compared to a 
1kbPlus ladder (NEB) and scored as either cut (+) or uncut (-).  A total of 260 cases and 
541 controls from the Tobago Prostate Cancer study were genotyped for the XbaI and 
PvuII polymorphisms. 
3.3 IMMUNOFLUORESCENCE ASSAY 
Serum samples from 154 Tobago prostate cancer and 147 controls were analyzed by 
enhanced immunofluorescent assay (IFA) (146).  A cutoff seropositivity level of 1:100 
was used and titer levels were determined by performing IFA on serially diluted samples.  
Samples were tested in duplicate by the same reader who was blinded to patient 
genotypes and case/control status (86). 
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3.4 GENOTYPING DATA ANALYSIS 
A sample of 154 cases and 147 controls with overlapping genotyping and serologic 
results were included in the data analysis.  Chi square tests were used to determine 
significance of serologic and genotyping results. Estimation of the odds ratio (OR) was 
done by condensing genotype categories into 2 groups (G/G, G/A and A/A) and 
combining this data with HHV8 seropositivity status, resulting in a total of 4 groups.  The 
reference group for the logistic regression model was comprised of individuals who were 
seronegative for HHV8 infection and had the low risk genotype (A/A).  Two-sided tests 
of statistical significance were used in the analysis.  Androgen receptor repeat sizes were 
grouped into 2 categories, long (≥20) and short (<20) repeats and analyzed as a 
dichotomous variable. 
 
3.5 COMPUTATIONAL SEARCH FOR ESTROGEN RESPONSE 
ELEMENTS 
A position specific scoring matrix was constructed by aligning 45 experimentally 
validated estrogen response element sequences (table 5) published by Vega et al (50). A 
count matrix was created using the enoLOGOS program (147) (sequence LOGO seen in 
Figure 7) and was converted to a log transformed weight matrix using the equation:  wbi = 
-ln ((cbi + 0.25)/(n+1)).  The weight matrix was then used to score 750bp sequences 
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upstream of each open reading frame in the HHV8 genome (Accession # NC_003409) 
using a 13bp sliding window.   
The false positive rate of the algorithm was evaluated using 2 methods.  First, the 
algorithm was used to scan all possible reading frames of a 10,000bp sequences that were 
composed of coding exons (excluding 1st exons) randomly selected from the human 
genome (NCBI Build 36.1).  Transcription factor binding sequences are uncommonly 
found in protein coding sequences (with the exception of the 1st exon), therefore this 
sequence should not be enriched for ERE sequences. As a second method, we scanned a 
total of 100 sequences 10,000bp in length that had been randomly generated based on the 
dinucleotide content of exons in the human genome. Both methods were found to 
produce highly similar results.  True detection rates were determined by scanning all 
possible reading frames of an artificial sequence which contained each of the ERE 
sequences used to construct the weight matrix.  Significance cutoff scores were 
determined by setting sensitivity to 80% and specificity to 99.99% (1 false positive per 
10,000bp). Sequences that scored above the significance cutoff and were located within 
750bp of the ATG start site of the test gene were designated as candidate sequences for 
further analysis.   
Sequences scoring above the significance cutoff score were then given individual 
p-values.  These values were determined by generating all possible 13-mer sequences and 
scoring them using our position-specific scoring matrix.  Each of the 13-mer sequences 
was then ranked by score.  To determine the probability of finding a sequence at or above 
a particular score, our experimental sequences were then compared to the ranked list of 
13-mers.  Therefore our p-values indicate the likelihood of finding a sequence at or above 
that particular score. 
 39
 
Table 5. List of Experimentally Validated Estrogen Response Element Sequences 
Number Gene Location Sequence 
1 PDZK1 chr1:143,215,756-143,215,768 GGTCAcccAGTCC 
2 ADORA1 chr1:199,790,269-199,790,281 GGTTAgggTGACC 
3 ADORA1 chr1:199,790,414-199,790,426 GGTGTcttTGACC 
4 AGT chr1:227,156,613-227,156,625 GGGCAtcgTGACC 
5 GREB1 chr2:11,603,634-11,603,646 GGTCAaaaTGACC 
6 GREB1 chr2:11,615,324-11,615,336 GGTCAtcaTGACC 
7 GREB1 chr2:11,621,861-11,621,873 AGTCAgtgTCACC 
8 GREB1 chr2:11,623,258-11,623,270 GGTCAttcTGACC 
9 CYP1B1 chr2:38,214,993-38,215,005 GGTCGcgcTGCCC 
10 CYP1B1 chr2:38,215,049-38,215,061 GGTCAaagCGGCC 
11 LTF chr3:46,481,739-46,481,751 GGTCAaggCGATC 
12 AREG chr4:75,676,340-75,676,352 GGACAaggTGTCC 
13 ELOVL2 chr6:11,154,748-11,154,760 GGTCAtctTGATG 
14 VEGF chr6:43,844,381-43,844,393 AATCAgacTGACT 
15 LY6E chr8:144,170,802-144,170,814 GGACAagaTGACC 
16 PTGES chr9:129,597,654-129,597,666 GGACAgccTGGCC 
17 CASP7 chr10:115,428,398-115,428,410 GGTCAgggTGAAC 
18 CASP7 chr10:115,428,492-115,428,504 GGTCGgggTGAAC 
19 CASP7 chr10:115,428,572-115,428,584 GGTCAgggTGAAC 
20 CASP7 chr10:115,428,612-115,428,624 GGTCAgggTGAAC 
21 CASP7 chr10:115,428,652-115,428,664 GGTCAgggTGAAC 
22 CASP7 chr10:115,428,689-115,428,701 GGTCAgggTGAAC 
23 CASP7 chr10:115,428,743-115,428,755 GGTCAgggTGAAC 
24 CTSD chr11:1,741,924-1,741,936 GGCCGggcTGACC 
Table 5 Continued 
25 PGR chr11:100,504,595-100,504,607 GGTCAccaGCTCT 
26 PGR chr11:100,505,180-100,505,192 GCAGGagcTGACC 
27 SCNN1A chr12:6,355,536-6,355,548 GGTCAgccTCACC 
28 GAPDH chr12:6,513,208-6,513,220 GGACAtcgTGACC 
29 ESR2 chr14:63,879,248-63,879,260 GGTCAggcTGGTC 
30 FLJ30973 chr15:55,670,850-55,670,862 GGGCAgtgTGGCC 
31 FLJ30973 chr15:55,671,545-55,671,557 GGTCAcccTGCTC 
32 ABCA3 chr16:2,319,793-2,319,805 GGTCAcggTGTTC 
33 IGFBP4 chr17:35,849,113-35,849,125 GGTCAttgTGACA 
34 TRIM25 chr17:52,323,321-52,323,333 GGTCAtggTGACC 
35 BCL2 chr18:59,136,673-59,136,685 GGTCGccaGGACC 
36 MGC26694 chr19:19,035,118-19,035,130 GTTCAgagTGACC 
37 GRAMD1A chr19:40,182,519-40,182,531 GGCCTggcTGACC 
38 ACTN4 chr19:43,897,093-43,897,105 GGTCActgTGACT 
39 GPR77 chr19:52,532,131-52,532,143 GGTCActcTGACA 
40 C3 chr19:6,671,884-6,671,902 GGTGGcccTGACC 
41 NRIP1 chr21:15,359,833-15,359,845 GGTCAaagTGACC 
42 TFF1 chr21:42,659,626-42,659,638 GGTCCtggTGTCC 
43 TFF1 chr21:42,659,906-42,659,918 AGCCAagaTGACC 
44 TFF1 chr21:42,660,106-42,660,118 GGTCAcggTGGCC 
45 CRKL chr22:19,595,695-19,595,707 AGTCAatcTAACC 
 
Adapted from Vega et al GenomeBiology (50) 
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 Figure 7. Sequence LOGO Representing the Consensus ERE Sequence Included in the Position-
Specific Scoring Matrix 
3.6 ELECTROPHORETIC MOBILITY SHIFT ASSAY 
Short oligonucleotide probes were synthesized to containing each of the candidate ERE 
sequences, as well as approximately 20bp of flanking sequence around each ERE (table 
6).  A sequence containing the ERE from the Xenopus vitellogenin A2 gene was used as 
a positive control for the analysis.  Single stranded probes were hybridized to form a 
double stranded DNA probes and end labeled with 32P using T4 polynucleotide kinase 
(NEB).  Unincorporated radionucleotides were removed using the Qiagen Nucleotide 
Removal kit.  Nuclear protein extracts were prepared from a T-75 flask of MCF-7 cells 
using the NucBuster Protein Extraction kit (Novagen) according to the manufacturer’s 
instructions.  Protein concentrations were determined using the Bradford assay (BioRad) 
according to the manufacturer’s instructions.  Binding reactions were prepared by 
incubating 10ug of nuclear protein extract with 1ul of labeled DNA probe in the presence 
of 0.03125ug of polydI:dC to prevent non-specific binding.   After a 30 minute 
incubation at room temperature, the binding reactions were mixed with 6x Maniatis gel 
loading buffer IV (148) and run on a 6% nondenaturing polyacrylamide gel in 0.1X TBE 
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at 200V for 2 hours.  Gels were then placed in plastic wrap and allowed to expose a 
phosphorimager plate overnight at room temperature.  Plates were then read using a 
Molecular Dynamics phosphorimager.  Cold competition assays were performed as 
above, but with the inclusion of increasing amounts of unlabelled DNA probe (0, 2, 5, 10, 
50, 100, 500, or 1000 fold) in the binding incubation step. 
 
Table 6. Oligonucleotide Probes Used in Electrophoretic Mobility Shift Assays 
ERE Forward Primer Reverse Primer 
Vitellogenin 
control 
5’-CTA-GAA-AGT-CAG-GTC-
ACA-GTG-ACC-TGA-TCA-AT-3’ 
5’-ATT-GAT-CAG-GTC-ACT-
GTG-ACC-TGA-CTT-TCT-AG-3’ 
ORFK8 5’-CTG-CAA-CCG-GTC-AGG-
GCG-ACC-TCG-GCG-AC-3’ 
5’-GTC-GCC-GAG-GTC-GCC-
CTG-ACC-GGT-TGC-AG-3’ 
ORF49 5’-CAA-TCT-ACG-ATC-CCA-
GTG-ACC-TAA-ATA-GAG-3’ 
5’-CTC-TAT-TTA-GGT-CAC-
TGG-GAT-CGT-AGA-TTG-3’ 
ORF74 5’-GAC-AGA-AAG-GTC-ACC-
TGG-CCC-AAA-CGG-AG-3’ 
5’-CTC-CGT-TTG-GGC-CAG-
GTG-ACC-TTT-CTG-TC-3’ 
 
3.7 NOSHIFT ASSAY OF ESTROGEN RESPONSE ELEMENTS 
The NoShift Transcription factor assay was used to confirm the identity of proteins 
observed to bind ERE sequences in the EMSA analysis.  The NoShift Transcription 
Factor Assay estrogen receptor α kit was obtained from Novagen.  Oligonucleotide 
probes with identical sequence to those used for EMSA experiments (Table 6) were 
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synthesized with 5’ biotin labels (Proligo) and nuclear protein extracts were prepared 
using the NucBuster kit as per the manufacturer’s instructions.  Binding reactions were 
prepared by incubating 5ul of 4x NoShift Bind buffer, 1ul of poly-dI-dC reagent 
(Novagen), 1ul of salmon sperm (Novagen), 1ul of 10pmol/ul biotinylated 
oligonucleotide probe, 5ul MCF-7 nuclear extract, and 7ul of nuclease-free H20. Binding 
reactions were then incubated on ice for 30 minutes.  Wells of a streptavidin-coated 
microplate (Novagen) were washed 3 times with 200ul of 1x NoShift Wash Buffer 
(Novagen).  80ul of 1x NoShift Bind buffer was added to each binding reaction and the 
entire reaction was added to the washed, streptavidin-coated plate.  The plate was then 
sealed and incubated at 37°C for 1 hour.  Contents of the plate were then poured off and 
the plate washed three times with 200ul of 1x NoShift Wash buffer (Novagen).  Next, a 
mouse monoclonal antibody (Novagen) recognizing the human estrogen receptor α 
protein (clone TE-111) was diluted 1:1000 in NoShift Antibody dilution buffer 
(Novagen) and 100ul of the diluted antibody solution was added to each well.  The plate 
was sealed and incubated at 37°C.  After 1 hour the contents were removed by inverting 
the plate and washed three times with 200ul NoShift Wash buffer.  A 1:100 dilution of 
HRP-conjugated secondary antibody (Novagen) was prepared and 100ul was added to 
each well.  The plates was again sealed and incubated at 37°C for 30 minutes.  Contents 
of the plate were then removed and the plate was washed five times with 200ul of 1x 
NoShift Wash buffer.  100ul of tetramethylbenzidine (TMB) substrate was then added to 
each well and incubated at room temperature until a blue color change was observed.  
Finally 100ul of 1N HCL was added to stop the reaction and colorimetric readings were 
taken by measuring absorbance at 450nm using a microplate reader. 
3.8 QUANTIFICATION OF ESTROGEN INDUCTION USING LUCIFERASE 
REPORTER ASSAY  
To show that promoters found in the HHV8 genome to contain ERE sequences were 
responsive to estrogen treatment, we performed a series of reporter assays.  The 5’-
regions of candidate HHV8 genes found to contain ERE sequences were amplified by 
PCR using primer sets in table 7.  50ul PCR reactions were prepared using 28ul dH20, 
8.0ul 1.25mM dNTP mix (Invitrogen), 10x PCR buffer (Invitrogen), 2.0ul 50uM MgCl2, 
0.75ul of each 20uM primer, 0.2ul 5U/ul Taq polymerase.  PCR amplification was 
performed in an MJ Research thermocycler using 30 cycles of the following conditions: 
95°C for 30 seconds, 56.0°C for 30 seconds, 72°C for 30 seconds, followed by a final 10 
minute extension at 72°C. The K8 promoter region was found to contain 2 ERE 
sequences, therefore several truncated portions of the K8 promoter were created (figure 
8) in order to determine which of the 2 ERE sequences were necessary for the response to 
estrogen treatment.  
 
Figure 8.  Diagram of HHV8 Promoter Fragments Used in Luciferase Reporter Assays 
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PCR fragments for the K8FL, K8ERE1, and K8NoERE reporter constructs were 
cloned into the pGEM-T EASY plasmid (Promega) according to the manufacturer’s 
instructions. PCR fragments for the K8A, K8B, ORF49, and ORF74 constructs were 
initially cloned in the pCR2.1-TOPO plasmid vector using the Invitrogen™ TA-TOPO 
kit.  Next, pGEM-T EASY plasmids containing the K8FL, K8ERE1, and K8NoERE 
inserts were digested overnight with KpnI and SpeI (NEB).  The pCR2.1 plasmids 
containing K8A, K8B, ORF49, and ORF74 inserts were digested overnight using KpnI 
and XbaI (NEB).  Restriction digest reactions were then run on a 1% agarose gel in 1X 
TBE and the digested fragments were excised from the gel and purified using the 
QIAquick gel extraction kit (QIAgen) according to the manufacturer’s instructions. The 
purified inserts were then ligated using T4 DNA ligase (NEB) into KpnI/NheI digested 
pGL3-basic luciferase reporter vector from Promega™ (entire procedure illustrated in 
figure 9).  Presence and orientation of inserts was confirmed by restriction digest or direct 
DNA sequencing.  One-Shot competent cells (Invitrogen) were transformed with plasmid 
constructs using the heatshock method according to manufacturer’s instructions.  Single 
colonies were isolated from ampicilin-treated agar plates and used to grow glycerol 
stocks. Five hundred ml cultures of Luria-Bertani (LB) media treated with ampicilin were 
inoculated with 25ul of glycerol stock and grown overnight.  High purity plasmid DNA 
was prepared using a cesium chloride centrifugation density gradient protocol followed 
by phenol-chloroform extraction and resuspended in distilled water.  Plasmid DNA 
concentrations were determined using a Nanodrop spectrophotometer (Thermo). 
 Figure 9.  Illustration of Promoter Cloning Procedure 
 
 
 
 
 
 
 
 
 46
 47
Table 7.  PCR Primers Used for Amplifying HHV8 Upstream Regions Containing ERE Sequences 
for Cloning into pGL3 Luciferase Vectors 
ERE Forward Primer Reverse Primer 
K8FL 5’-GGT-CAT-GAC-GGA-GAC-CAA-
GG-3’ 
5’-GTG-TAA-ACG-TGT-AAC-CCT-
GCC-3’ 
K8B 5’-CGC-GCT-GTT-GTC-CAG-TAT-
TC-3’ 
5’-GTG-TAA-ACG-TGT-AAC-CCT-
GCC-3’ 
K8ERE1 5’-CCT-TCG-GTA-CCC-GGA-GTC-
3’ 
5’-GTG-TAA-ACG-TGT-AAC-CCT-
GCC-3’ 
K8NoERE 5’-CGA-GGT-ACC-AGG-AGT-CCG-
3’ 
5’-GTG-TAA-ACG-TGT-AAC-CCT-
GCC-3’ 
ORF49 5’-AGA-TCT-TGA-CAC-GCC-ACT-
CTC-TCC-TTA-G-3’ 
5’-AGA-TCT-GGT-CAC-TGG-GAT-
CGT-AGA-TTG-3’ 
ORF74 5’-CTA-GAT-GGA-CAC-CCC-GTG-
AAC-C-3’ 
5’-GGC-CTA-CAA-TAA-CAA-GTA-
GTA-TAG-G-3’ 
 
MCF7 and T47D cell lines were grown to approximately 70% confluency in 6-
well cell culture plates in 2ml of Roswell Park Memorial Institute (RPMI) 1640 media 
supplemented with 10% fetal bovine serum (FBS) and 1x gentamicin.  Media was 
removed by aspiration and 2ml of fresh OptiMEM (GIBCO) was added to each well.   
Transfection reactions were set by diluting 4ug of plasmid vectors in a total volume 250ul 
Optimem and adding 5ul of Lipofectamine reagent (Invitrogen) to 240ul of Optimem.   
Reagents were then combined and incubated for 30 minutes. The DNA:Lipofectamine 
complexes were then added to the cell culture plates.  Each plate included cells 
transfected with positive and negative control vectors.  The positive control vector, ERE-
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Luc, is composed of 2 estrogen response elements inserted into the HSV thymidine 
kinase promoter.  The empty pGL3 vector and pGL3-control vectors were used as the 
negative controls.  After 6 hrs media was aspirated from the wells and replaced with 2ml 
of phenol red–free RPMI media supplemented with 20% charcoal-stripped FBS.  The 
following morning half the wells were treated with 17β-estradiol (Sigma) at a final 
concentration of 10-8M.  After 18hrs, cell cultures were lysed with Promega GLO-Lysis 
buffer and cells were detached from plates using cell scrapers and frozen at -80°C.  Cell 
lysates were then thawed and 100ul of lysate was incubated with an equal volume of 
Promega Bright-Glo Luciferase substrate.  Photon emission from each sample was 
measured using an LJL Catalyst™ plate reader.   
The level of induction by estrogen was calculated by taking the ratio of the 
intensity of estrogen induced divided by uninduced sample.  The significance for each 
vector was determined using a 2-sample paired t-test of the raw values of the induced 
compared to uninduced samples in each paired sample on the plate.   
3.9 ESTROGEN INDUCTION OF HHV8 INFECTED BCBL-1 CELLS 
3.9.1 Cell culture and estrogen treatment 
BCBL1 cells containing the RTA gene under a doxycyclin-inducible promoter (TREx-
BCBL1-Rta) (149) were cultured in a T-125 flask in 300ml of RPMI media 
supplemented with 10% FBS and 1x Gentamicin for 3 days.  Cultures were pelleted by 
centrifugation and resuspended in 25ml of phenol red-free RPMI.  A cell count was 
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performed by trypan-blue assay.  Approximately 1x108 cells were added to three new T-
75 flasks in a total volume of 240ml of phenol red-free RPMI media supplemented with 
10% charcoal-stripped FBS and placed in a tissue culture incubator at 37°C with 5%CO2.  
After 4 hours, the initial T=0 timepoint was harvested and cells were treated with either 
10-6M 17β-estradiol, 1X 12-O-tetradecanoylphorbol 13-acetate (TPA), or 20ul ethanol 
(mock).   
3.9.2 RNA preparation 
Time points were collected at 0, 2, 4, 8, and 16 hours by removing 40ml of cell 
suspension (~ 1.8x107 cells total) from each flask and pelleted by centrifugation.  The 
supernatant was removed by aspiration and 2 ml of Trizol reagent (Invitrogen) was 
added.  RNA isolations were performed according to the manufacturer’s instructions with 
the exception that all RNA preps were incubated at -80°C for 30 minutes during the RNA 
precipitation step.  Purified RNA solutions were stored at -80°C.    
3.9.3 Preparation of cDNA by reverse transcription 
RNA samples were quantified using a NanoDrop spectrophotometer (Thermo).  All 
samples were run in duplicate using 400ng of DNase-treated total RNA per reaction.  
Reverse transcription was performed by preparing a mastermix solution containing 
Superscript II (GibcoBRL) and samples were  incubated in a thermocycler (MJ Research) 
at 35°C for 10 minutes, 48°C for 30 minutes, and 95°C for 5 minutes.  Samples volumes 
were brought up to 100ul using nuclease-free water (Ambion) and stored at -20°C.   
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3.9.4 Taqman Realtime PCR quantification of HHV8 K8 mRNA expression 
Realtime PCR primers and probes for HHV8 K8 were prepared using Primer Express ver 
2.1 (ABI) (table 8).  RT-PCR was performed using 1X Taqman Universal PCR Master 
Mix (ABI), 5uM FAM/TAMRA-labeled probe, 10uM forward and reverse primers, and 
20ng cDNA.  Control GAPDH expression was measured using 50nM JOE/TAMRA 
labeled probe.  RT-PCR was run using the following conditions:  50°C for 2 minutes, 
95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds, 60°C for 1 minute.  
Reactions were run in an ABI Prism 7700 Sequence Detector using SDS ver 1.7 (ABI) to 
detect fluorescence at 538nm (FAM), 546nm (JOE) and 582nm (TAMRA) in order to 
determine threshold cycle.  Baseline value was calculated by averaging the fluorescent 
values of cycle 3-15 and then adding 10 times the standard deviation.  All reactions were 
performed in duplicate and values were averaged.  Expression of K8 was normalized to 
GAPDH levels using the comparative Ct method (ABI Prism 7700 Sequence Detection 
System User Bulletin #2 Dec 11, 1997)  
 
Table 8.  PCR Primers and Taqman Probes Used in Quantifying K8 RNA Expression Levels. 
Name Sequence 
K8 Forward primer 5’-TCC-CAC-CAT-GTT-GAA-GCT-TG-3’ 
K8 Reverse primer 5’-TGA-TCC-ACA-CAA-AGT-CTG-GCA-3’ 
K8 Detection probe 5’-6FAM-TTC-TCC-CGG-ACG-ACG-GCA-CAA-T-
TAMRA-3’ 
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3.10 PHYLOGENETIC ANALYSIS 
In order to determine if ERE sequences were conserved in other evolutionarily related 
viruses, we computationally screened all gammaherpesviruses with a genome reference 
sequence deposited in the NCBI database.  Twelve viruses (listed in table 3) were 
computationally searched for ERE sequences as described in section 3.5.  Open reading 
frames found to have one or more ERE sequences scoring above the significance 
threshold score of 11.3127 (corresponding to 80% sensitivity and 99.99% specificity) and 
located within 750bp of the ATG were considered to have an ERE present.  Homology of 
genes was determined based on NCBI genome annotations, conserved gene synteny, and 
the phylogenetic comparison performed by Nicholas (150).  In order to determine the 
significance of identifying ERE sequences in the upstream region of multiple 
homologous genes, we performed a simulation analysis to determine the empirical 
likelihood of the event occurring by chance alone, rather than true evolutionary 
conservation.  To perform the simulation analysis, a new 750bp sequence was randomly 
generated based on the dinucleotide content of the original homolog sequence.  New 
randomly generated sequences were created for all homologs initially screened for ERE 
sequences. These new sequences were then searched for ERE sequences and counts of 
the number of simultaneous occurrences were retained.  This was repeated 10,000 times 
and the total number of repetitions where ERE sequences were found to occur 
simultaneously in multiple sequences was divided by the total number of repetitions to 
obtain the frequency of finding EREs in multiple homologs simply due to chance alone.   
 52
4.0  RESULTS 
4.1 GENOTYPING AND SEROLOGICAL RESULTS 
4.1.1 Individual analysis of ESR1, AR, and serology variables 
260 cases and 541 controls from the Tobago Prostate Cancer study were genotyped for 
the XbaI and PvuII polymorphisms located in intron 1 of the estrogen receptor alpha gene 
by PCR-RFLP analysis. 324 cases and 790 controls were genotyped for the androgen 
receptor polyglutamine (CAG) repeat.  282 cases and 291 controls from the same cohort 
underwent serological testing of HHV8 infection by enhanced immunofluoresence assay 
(IFA).  Data was analyzed using chi-square test and odds ratio values were determined by 
logistic regression.   Our analysis identified an association between the ERα (ESR1) XbaI 
G/G genotype (designated -/-) and an increased risk of prostate cancer (p=0.005; 
OR=2.48 [95%CI: 1.42-4.34]) (table 9).  These results confirm the findings of earlier 
studies that reported associations between ESR1 polymorphisms and prostate cancer risk 
(66).  Despite the presence of linkage disequilibrium between the XbaI and PvuII sites, 
we did not observe a significant association between the PvuII polymorphism and 
prostate cancer risk (data not shown). 
Several previous reports have found significant associations between the 
androgen receptor polyglutamine repeat and prostate cancer risk (151,152), however, our 
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analysis failed to identify an association between the short form of the androgen receptor 
polyglutamine repeat (<20 repeats) and prostate cancer risk (p=.63 OR=1.07 [95%CI: 
0.82-1.38].) (table 9).   
We also observed a statistically significant association between HHV8 
seropositivity and an increased risk of prostate cancer (p=0.001; OR=1.80 [95%CI: 1.28-
2.52]) (Table 9).  Our findings suggest that men from Tobago with serologic evidence of 
HHV8 infection are at an increased risk of prostate cancer.  Interestingly, our serological 
analysis found an overall high level of HHV8 seroprevalence in the Tobago population, 
with 23.1% (183 out of 793) individuals found positive for HHV8 antibodies (table 9).   
  
Table 9. Individual Analysis of Association Between Estrogen Receptor XbaI and HHV8 Serology 
with Prostate Cancer Risk 
Parameter Cases Non-Cases P(X^2) OR(95%CI) P(OR) 
ESR1 +/+ 122 (47%) 292 (54%) ---- 1.0 ---- 
ESR1 +/- 109 (42%) 221 (41%) ---- 1.18 (0.86-1.61) 0.30 
ESR1 -/- 29 (11%) 28 (5%) 0.005 2.48 (1.42-4.34) 0.002 
       
AR long 147 (45%) 371 (47%) ---- 1.0 ---- 
AR short 177 (55%) 419 (53%) 0.63 1.07 (0.82-1.38) 0.63 
      
HHV8 - 199 (67%) 411 (79%) ---- 1.0 ---- 
HHV8 + 96 (33%) 87 (21%) 0.001 1.80 (1.28-2.52) 0.001 
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4.1.2 Analysis of combined data 
When the hormone receptor genotype and serological results were analyzed in 
combination, we observed several interactions between hormone receptor genotypes and 
HHV8 serology which were associated with an increased risk of prostate cancer.  The 
first of these interactions was an association between the estrogen receptor alpha and 
HHV8, in which individuals with at least one XbaI G (-) allele who were seropositive for 
HHV8, were found to be at an even higher risk of prostate cancer than either of the 
factors independently (p=0.032; OR=3.10 [95%CI: 1.42-6.77]) (Table 10), indicating the 
presence of an interaction between these factors and prostate cancer risk.  A similar 
interaction was found between the short form of the androgen receptor repeat and HHV8 
seropositivity, that was significantly associated with prostate cancer risk (p= 0.044; 
O.R=2.46 [95%CI: 1.13-5.35]) (table 10). 
Further, when we performed a combined analysis of the ESR1 and AR 
polymorphisms with HHV8 seropositivity, we found that individuals who were 
seropositive for HHV8 infection and carried a mutant ESR1 XbaI allele, as well as the 
short form of the androgen receptor repeat had the highest risk of prostate cancer 
observed in the entire analysis (p=0.005; OR=9.5 [95%CI: 2.58-35.02]) (table 11). 
 
Table 10. Combined Analysis of Association Between Estrogen Receptor XbaI and HHV8 Serology 
with Prostate Cancer Risk 
 
Parameter Cases Non-Cases P(X^2) OR(95%CI) P(OR) 
HHV8 - 
&  ESR1 +/+ 
56 (36%) 66 (45%) ---- 1.0 ---- 
HHV8 - 
& Any ESR1 - 
45 (29%) 47 (32%) ---- 1.12 (0.66-1.94) 0.66 
HHV8 + 
& ESR1 +/+ 
24 (16%) 23 (16%) ---- 1.23 (0.66-1.94) 0.54 
HHV8 + 
& Any ESR1 - 
29 (19%) 11 (7%) 0.032 3.10 (1.42-6.77) 0.004 
      
HHV8- 
& long AR 
51 (33%) 52 (35%) ---- 1.0 ---- 
HHV8- 
& short AR 
50 (32%) 61 (42%) ---- 0.84 (0.49-1.43) 0.51 
HHV8+ 
& long AR 
24 (16%) 23 (16%) ----- 1.11 (0.55-2.23) 0.76 
HHV8+ 
& short AR 
29(19%) 12 (8%) 0.044 2.46 (1.13-5.35) 0.023 
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Table 11. Analysis of Combined ESR1, AR, and HHV8 Serology Results 
 
Parameter Cases Non-
Cases 
P(X^2) OR(95%CI) P(OR) 
AR long & ESR1+/+ 
&HHV8- 
28 (15%) 38 (21%) ---- 1.0 ---- 
AR short & 
ESR1- & HHV8+ 
21 (11%) 3 (1.6%) 0.005 9.5 (2.58-35.02) 0.001 
4.2 COMPUTATIONAL ANALYSIS OF ER BINDING SITES IN THE HHV8 
GENOME 
A computational search of the HHV8 genome reference sequence identified 20 predicted 
ER binding sites (table 12).  These 20 ERE sequences were located in the upstream 
regions of 18 open reading frames in the HHV8 genome and were distributed relatively 
randomly (figure 10), with the exception of a cluster of predicted sites located in the 
region containing several genes involved in transcriptional control and regulating the 
viral latent/lytic life cycle (figure 11).  In this region, the two highest scoring hits in our 
analysis were located in the promoter region of the K8 gene (EREs 4 and 5 in figure 11).  
The K8 EREs were located 314bp and 399bp 5’ of the ATG start site, in a region 
previously found to be the K8 promoter (153).    The K8 gene encodes a basic leucine 
zipper (bZIP) protein that is a homolog of the EBV BZLF1 gene (154).  However, while 
BZLF1 is a known transcriptional activator in EBV (155), K8 has been shown to repress 
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lytic reactivation by inhibiting the major lytic switch gene, ORF50/Rta (156).  K8 has 
also been shown to bind to specific DNA sequences in the lytic origin of replication 
(157). 
Another high-scoring ERE sequence was also located in a non-coding region 
upstream of the ORF49 gene and the second exon of ORF50 (ERE1 in figure 11).  Both 
of these genes have been shown to function as transcriptional activators.  Expression of 
ORF49 has been reported to act cooperatively with ORF50 to increase the activation of 
lytic gene expression (158).  An expanded analysis of this region identified an additional 
2 ERE sequences located inside of the ORF50 reading frame, 666 and 682 bp 5’ of the 
ORF49 ATG (EREs 2 and 3 in figure 11).  Therefore a total of 5 high scoring EREs were 
identified in this cluster of genes. 
We selected candidate ERE sequences for further analysis based on 3 criteria: 
how closely the candidate ERE matched the known ERE consensus, the known 
functional role of the gene in important transcription regulation and signaling pathways, 
and finally, a previously demonstrated role in oncogenesis.  Based on these criteria, we 
selected EREs in 3 genes for further functional analysis: K8, ORF49, and ORF74.   The 
K8 and ORF49 genes are interesting candidates because they both have a major role in 
regulating HHV8 gene expression and control of the lytic/latent switch.  Due to its 
location in the non-coding region shared by ORF49 and ORF 50, the ORF49 ERE could 
also have had an effect on ORF50 expression.  The third ERE selected for our follow up 
analysis was located upstream of the ORF74 gene.  ORF74 encodes a G-protein coupled 
receptor which has homology to the human IL8 receptor and has been shown to be 
involved in chemokine signaling (124,125).  Expression of ORF74 has been shown to 
transform mouse fibroblasts and forms tumors in nude mice (126).  
Table 12. ERE Sequences Identified in the HHV8 Genome 
Rank ORF Name Sequence Distance Strand Score Sigificance 
1 ORF K8 BZLF1 homolog GGTCAGGGCGACC 314 F 7.177 1.74344E-06 
2 ORF K8 BZLF1 homolog GGGGAGGGTGACC 399 R 9.586 2.68966E-05 
3 ORF57 Transcriptional activator GGTGAGGGGGACC 260 R 9.718 3.08454E-05 
4 ORF53 Envelope glycoprotein GGTCAGGATGAAA 268 F 9.989 4.0248E-05 
5 ORF56 DNA replication protein homolog; EBV 
BSLF1 homolog 
GGACAACGTCACC 153 F 9.998 4.06504E-05 
6 ORF50 transactivator homolog; EBV BRLF1 
homolog 
GGTCACTGGGATC 48 R 10.397 5.95003E-05 
7 ORF29a packaging protein homolog; EBV BGRF1 
homolog 
GGCCTGTGTGACC 428 R 10.403 5.99176E-05 
8 ORF31 EBV BDLF4 homolog GGTCTCGCTGACT 17 F 10.481 6.42985E-05 
9 ORF39 glycoprotein M GGACACGCTGACG 291 R 10.561 6.89328E-05 
10 ORF K14 adhesion molecule vAdh homolog AGTCAGCCGGACC 63 F 10.576 6.98715E-05 
11 ORF9 DNA polymerase homolog; EBV BALF5 
homolog 
GGTGAAGATGATC 376 F 10.617 7.26432E-05 
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Table 12 Continued 
12 ORF53 Envelope glycoprotein GGGCATGATGAAC 220 F 10.619 7.28667E-05 
13 ORF66 EBV BFRF2 homolog  GGGCAGGATGACT 368 F 10.850 8.96603E-05 
14 ORF42 EBV BBRF2 homolog GCTCAGCGTCACC 215 F 10.991 0.0001017 
15 ORF K5  BHV4-IE1 homolog GGACAAGTTGTCC 324 R 11.002 0.000102699 
16 ORF74 G protein coupled receptor GGGCCAGGTGACC 181 R 11.035 0.000105992 
17 ORF54 dUTPase homolog; EBV BLLF3 homolog GGCCACCGTGGAC 22 F 11.109 0.000112846 
18 ORF32 EBV BGLF1 homolog; DNA packaging GGACGGCGTCACC 219 F 11.132 0.000114769 
19 ORF60 ribonucleotide reductase, small subunit  GGTCCGGGTAACC 99 R 11.157 0.000116855 
20 ORF69 BFLF2 homolog GGTCGCAGTGGAC 186 F 11.246 0.000126064 
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 Figure 10. Distribution of Predicted Binding Sites in the HHV8 Genome. 
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Figure 11. Cluster of Predicted ER Binding Sites in HHV8 Regulatory Region 
 
4.3 DETERMINATION OF ER BINDING TO ERE CANDIDATE SEQUENCES 
4.3.1 Electrophoretic mobility shift assay 
In order to show that the sequences identified in the HHV8 genome with a high degree of 
similarity to the ERE consensus sequence were actually able to bind ER proteins, we performed 
electrophoretic mobility shift assays (EMSA).  Radiolabled DNA probes were synthesized to 
contain candidate ERE sequences identified in the 5’-region of the K8, ORF49, and ORF74 
genes.  Incubation of these probes with nuclear extracts isolated from MCF7 and HCT116 cells 
was found to slow band migration resulting in a band shift (Figure 12; HCT116 data not shown).  
This observation indicates proteins in the nucleus of MCF7 and HCT116 cells were able to bind 
these candidate sequences in a manner similar to the Xenopus vitellogenin positive control 
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probe.   MCF7 cells are known to express high levels of the alpha ER while HCT116 cells 
express primarily the beta receptor (159), therefore it is likely that both ERα and β are capable of 
binding each of our candidate ERE sequences. 
 
 
Figure 12. Results of Electrophoretic Mobility Shift Assay of Candidate ERE Sequences 
 
 
In order to show that binding of proteins to probes containing ERE sequences was 
occurring in a specific manner and not an artifact resulting from non-specific binding, we 
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performed a cold competition assay.  In this assay, increasing amounts of unlabeled probe were 
added to the binding reactions to show that the proteins bound to radiolabeled DNA probes could 
be competed off by the presence of a large excess of unlabeled probe.   Results of the cold 
competition assay (figure 13) indicated that all 3 of the experimental probes and the positive 
control could be competed off by an excess of probe.   
 
 
Figure 13. Cold Competition EMSA of HHV8 ERE Sequences 
 63 
 4.3.2 NoShift transcription factor assay 
While the results of EMSA experiments strongly indicated that both estrogen receptors were 
capable of binding to ERE sequences located in front of the K8, ORF49 and ORF74 genes, other 
DNA binding proteins could have caused the observed band-shift.  Therefore to confirm that the 
estrogen receptor is binding to our DNA probe, we utilized the NoShift transcription factor assay 
(Novagen), which utilizes a monoclonal antibody to the human estrogen receptor alpha protein.  
The results of the NoShift analysis confirmed the identity of this protein as the alpha estrogen 
receptor (figure 14).  Our results indicated that all three experimental probes bound the estrogen 
receptor alpha protein at levels similar to the positive control probe include with the kit, but 
slightly less than the vitellogenin positive control.   
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 Figure 14. NoShift Transcription Factor Assay of HHV8 ERE Sequences. 
 
4.4 QUANTIFICATION OF HHV8 PROMOTER RESPONSE TO ESTROGEN 
TREATMENT 
4.4.1 Luciferase reporter assay 
Binding of ER proteins to sequences with a high similarity to the consensus ERE was expected, 
however it remained unknown if binding of estrogen receptors to these ERE sequences would 
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modify target gene transcription in the context of the full promoter.   Therefore we used a 
luciferase reporter assay to determine whether sequences found to contain ERE sequences were 
responsive to estrogens.  Regions upstream of the K8, ORF49, and ORF74 genes were 
successfully cloned into the pGL3-basic vector.  Presence and orientation of the K8 inserts were 
confirmed by restriction digest mapping, while the ORF49 and ORF74 inserts were confirmed by 
DNA sequencing.  The optimal amount of plasmid for use in transient transfections was 
optimized by transfecting cells with serial dilutions of the pERE-tk-LUC positive control and 
selecting the concentration that provided the highest level of response to estrogens in the reporter 
assay.  MCF-7 cells expressing ER-alpha were then transfected and treated with 10-8 M 17β-
estradiol.  Luciferase reporter expression was then measured and levels of cells treated with 
estrogen were compared to untreated cells.  Estrogen treatment was found to induce a 5-fold 
increase in expression of our positive control and no induction of the empty pGL3-basic vector 
which contains no EREs (figure 15).  We saw a statistically significant 2 fold increase 
(p<0.0001) in expression in the reporter plasmid containing the full length K8 promoter region 
(figure 15).  No significant increases with estrogen treatment were observed in MCF-7 cells 
transfected with reporter plasmids containing the ORF49 or ORF74 EREs (figure 15).  
Therefore, of all three experimental constructs, the K8 promoter exclusively appears to be 
responsive to estrogen treatment in MCF-7 cells expressing the estrogen receptor α.   
Because the K8 promoter was found to contain 2 ERE sequences in close proximity, a 
series of truncated promoter constructs (shown in figure 8) were created to determine which of 
the EREs contributed to the observed response to estrogen.  We also sought to confirm that other 
DNA elements, such as AP-1 or SP1 sites, in the K8 promoter were not acting in an indirect 
mechanism to increase reporter transcription in response to estrogens.  A truncated promoter 
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construct in which approximately 400bp of the 5’-flanking sequence was deleted upstream of the 
2 identified ERE sequences (construct K8B in figure 8), showed significant response to estrogens 
(figure 16).  This response was similar to levels observed in the full length construct, indicating 
that DNA elements upstream do not to contribute to the observed estrogen response.  Deletion of 
both ERE sequences (construct K8-NoERE in figure 8) resulted in a substantial decrease in the 
response to estrogens (Figure 16), indicating that the region containing the 2 ERE sequences was 
required for estrogen response.   A small, but statistically significant increase in expression was 
seen in this construct lacking both ERE sequences (statistical analysis shown in table 13).  This 
indicates that DNA elements downstream of the EREs have a minor contribution to the response 
to estrogens as well.  This minor response is likely a product of estrogen receptors acting through 
tethering at an AP-1 site located 27 bp downstream (position 74576-74585 in NC_003409) of the 
region containing ERE sequences.  Deletion of the upstream ERE (construct K8ERE1 in figure 
8) resulted in a similar substantial decrease in response to estrogens (Figure 8), suggesting that 
either the upstream ERE is primarily responsible for the estrogen response or that the presence of 
both ERE sites is required for the transcriptional response to estrogens.  This would be consistent 
with the hypothesis that both EREs act together as an estrogen response unit to carryout the 
response to estrogens.  
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Estrogen Treatment of MCF7 Cells
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Figure 15. Results of Luciferase Reporter Assay of K8, ORF49 and ORF74 Constructs Treated with 
Estrogens 
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Estrogen Treatment of MCF7 Cells
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     Figure 16.  Results of Luciferase Reporter Assay of Truncated K8 Constructs Treated with Estrogens 
 
Table 13. Statistical Analysis of Luciferase Response to Estrogen Treatment 
Construct Mean Significant p value 
K8FL 2.096 [± 0.06631] Yes <0.0001 
K8B 2.083 [±0.1184] Yes <0.0001 
K8ERE1 1.229 [±0.05610] Yes 0.0083 
K8NoERE 1.224 [±0.04074] Yes 0.0027 
K8A 0.9357 [±0.03126] No 0.1831 
ORF49 0.9789 [±0.03229] No 0.4388 
ORF74 1.126 [±0.08346] No 0.2973 
ERE-tk-luc 4.693 [±0.2311] Yes <0.0001 
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 4.4.2 Treatment of BCBL1 cells with estrogens 
Our analysis using luciferase reporter constructs indicated that the K8 promoter was responsive 
to estradiol treatment.  We therefore sought to determine whether this estrogen response was 
observed in the natural context of the entire viral genome, rather than a reporter construct.  
Human BCBL-1 cells (derived from a primary effusion lymphoma) that were latently infected 
with HHV8, were treated with estrogens.  K8 mRNA levels were monitored using Taqman 
realtime PCR over the course of 16 hours.  Results indicated that K8 mRNA levels did not 
appear to deviate from levels observed in untreated control cells (Figure 17).  However, a 
significant increase in K8 expression was seen in cells treated with TPA, which is a known 
activator of K8 and HHV8 lytic gene expression.  Therefore estrogen treatment does not appear 
to have a significant effect on HHV8 K8 expression in latently infected BCBL-1 cells.   
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   Figure 17.  Effect of Estrogen Treatment on K8 mRNA Expression Levels 
 
 70 
4.5 COMPUTATIONAL ANALYSIS OF CONSERVATION OF ERE SEQUENCES 
IN THE GAMMAHERPESVIRUSES 
A total of 12 members of the gammaherpesvirus family listed in table 3 were computationally 
screened for ERE sequences.  DNA sequences 750bp in length upstream of each open reading 
frame were searched using the computational algorithm used in our analysis of the HHV8 
genome.  We compared these results to the list of HHV8 genes found to have EREs present in 
their upstream regions.  We identified several viral homologs which had ERE sequences present 
in multiple phylogenetically related viruses.  In particular, ERE sequences were identified in 3 
out of 7 (p=0.1035) gammaherpesviruses with a homolog of the K8 bZIP gene (Table 14 & 
Figure 18).  We also identified ERE sequences in 6 out of 10 viruses (p=0.0029) with an ORF74 
(IL8R-like, G-protein coupled receptor) homolog (Table 15 & Figure 19).  In the case of 
herpesvirus saimiri (HVS), the pirating of a high activity thymidylate synthase gene has resulted 
in a highly AT-biased genome (160) and only a single ERE sequence was located in the entire 
genome.  Intriguingly, this sequence was located just inside of the HVS ORF 74 coding region, 
in the promoter region of the ORF73/LANA gene, which has been shown  in HVS to repress 
lytic reactivation by repressing ORF50 expression, similar to the activity of HHV8 K8 (161). 
Unexpectedly, we identified a highly conserved ERE in the upstream region of 8/11 
(p<0.0001) gammaherpesviruses with a homolog of the glycoprotein M (gM) gene (Table 16 & 
Figure 20).  In all cases, these conserved EREs did not appear to be present due to conserved 
amino acid sequence of an upstream gene.   
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Table 14. Estrogen Response Elements Upstream of K8 (bZIP) Homologs 
Virus Gene ERE Found Sequence 
HHV8 K8 Yes GGTCAGGGCGACC 
GGGGAGGGTGACC 
EBV BZLF1 Yes GGACGAACTGACC 
RRV bZIP No ----- 
AhV1 A6 Yes GGTCACGGGGTTC 
CalHV3 ORF43 No ----- 
CerHV15 BZLF1 No ----- 
OHV2 Ov6 No ----- 
 
 
Figure 18. Phylogenetic Tree Illustration of Gammaherpesviruses with Conserved ERE Sequences in Front of 
K8 Homologs 
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 Table 15. Estrogen Response Elements Upstream of ORF74/GPCR Homologs 
Virus Gene ERE Found Sequence 
HHV8 ORF74 Yes GGGCCAGGTGACC
EBV BILF1 No ----- 
RRV ORF74 Yes GGTCCAGTTGACC 
MHV68 ORF74 Yes GGCCAAGACAACC
AHV1 A5 No ----- 
CalHV3 ORF6/BILF1 Yes GGTTAAGGTGACA
CerHV15 BILF1 No ----- 
HVA ORF74 No ----- 
OHV2 Ov5 Yes GGGCATCCTGTCC 
EHV2 ORF74/E1/E6 Yes/Yes/No GGGCAGGCTGACC
GGTTAGTGTGTCC 
HVS ORF74 No ----- 
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 Figure 19. Phylogenetic Tree Illustration of Gammaherpesviruses with Conserved EREs in Front of ORF74 
Homologs 
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 Table 16. Estrogen Response Elements Upstream of Glycoprotein M Homologs 
Virus Gene ERE Found Sequence 
HHV8 ORF39 Yes GGCGACGGTGACC
GGACACGCTGACG
GGTCTGGGTGTTC 
EBV BBRF3 Yes GGGCATCGTGCCC 
GGTCAACGCGCCC
RRV ORF39 No ----- 
MHV68 ORF39 Yes GGACAGTCTGACC
AHV1 ORF39 Yes GGGCAACCTGGCC
BHV4 ORF39 Yes GGTCATGGTGGAT 
CalHV3 ORF39 Yes GGTCATGCTGTCC 
CerHV15 BBRF3 Yes GGGCATCGTGCCC 
HVA ORF39 No ----- 
OHV2 ORF39 No ----- 
EHV2 ORF39 Yes GGTCAGGGTGACT
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 Figure 20. Phylogenetic Tree Illustration of Gammaherpesviruses with Conserved ERE Sequences in front of 
Glycoprotein M Homologs 
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5.0  DISCUSSION 
5.1 RATIONALE 
Prostate cancer is a complex disease with both genetic and environmental factors.  The 
Caribbean nation of Tobago has one of the highest reported screening-detected prevalence of 
prostate cancer in the world (3).  The unique genetic ancestry of Tobago makes it an ideal 
population for investigating genetic risk factors for prostate cancer.  Here we report the 
discovery of a novel interaction between specific human genetic variation and viral infection that 
is associated with an increased risk of prostate cancer.  To further characterize this interaction, 
we have performed a detailed functional analysis and characterized a previously unreported 
biological interaction between these associated factors.   
A number of risk factors have been proposed to be important contributors in the etiology 
of prostate cancer.  The growth and development of the prostate gland have been shown to be 
strongly regulated by the action of steroid hormones (14).  Abnormal levels of these hormones 
have been shown to have profound effects on the prostate and influence on the risk of prostate 
cancer later in life (16).  However, circulating levels of these hormones are unlikely to be 
responsible for differences in prostate cancer risk (15,19).  Pathogens have also been 
hypothesized to be a risk factor for prostate cancer.  Associations between certain types of risky 
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sexual behavior and increased prostate cancer risk suggest that sexually transmitted diseases 
(STDs) may play an important role (81).     
Several recent reports have found associations between prostate cancer risk and genetic 
loci involved in immune response to pathogens (162,163). These genes, the macrophage 
scavenger receptor (MSR1) and ribonuclease L (RNASEL), play various important roles in 
mediating the immune response to pathogens (164,165).  However our recent investigation of the 
involvement of these loci in prostate cancer risk in the Tobago population failed to find a 
significant association with prostate cancer (166)(Shea unpublished).  Further, the specific 
mechanism by which these genes contribute to prostate cancer risk has yet to be described.  
Therefore, while genes involved in immune response appear to be important factors in prostate 
cancer pathogenesis, variation in the MSR1 and RNASEL genes does not appear to contribute 
significantly to the increased risk observed in Tobago.   
We therefore sought to investigate whether genetic variation in steroid hormone receptors 
contributed to prostate cancer risk independently or through gene x environment interactions 
with pathogen infection.   Results of our preliminary analysis identified statistically significant 
associations between the estrogen receptor XbaI polymorphism with a modestly increased risk of 
prostate cancer (OR=2.48 [95%CI: 1.42-4.34]).  Serological evidence of HHV8 infection was 
also found to be a risk factor for prostate cancer (OR=1.80 [95%CI: 1.28-2.52]).  Additionally 
we identified several previously unreported gene x environment interactions.  Individuals who 
carried at least one mutant estrogen receptor allele and were seropositive for HHV8 infection 
were found to be at over 3-fold increased risk of prostate cancer (OR= 3.10 [95%CI: 1.42-6.77].  
This level of risk was greater than the sum of the individual factors combined, indicating 
interaction between these factors.  A similar interaction was found in HHV8 seropositive men 
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who carried at least one short AR allele (OR=2.46 [95%CI: 1.13-5.35]).  Finally a third 
significant interaction was observed in men who carried at least one mutant ER allele, one or 
more short AR alleles, and were seropositive for HHV8 infection (OR= 9.5 [95% CI: 2.58-
35.02]).  Therefore our finding strongly suggests that an interaction exists between sex hormone 
receptors and HHV8 infection and that this interaction is an important factor in prostate cancer 
risk.   
While these findings suggest an intriguing link between these factors, the underlying 
mechanism linking these factors together is unclear.  However, several observations regarding 
the epidemiology of Kaposi’s sarcoma provide intriguing evidence for a role of hormones in 
HHV8 biology.  Despite similar levels of HHV8 infection among men and women, men are at a 
substantially higher risk of developing KS (4).  The underlying mechanism explaining this sex 
bias has yet to be determined, however sex hormones have been hypothesized to play a role.  
Estrogens are the primary female sex hormone and regulate the expression of a wide number of 
genes throughout the genome through several distinct mechanisms.   One of these mechanisms, 
called the classical pathway, functions through the binding of estrogens to a hormone receptor 
protein which translocates to the nucleus and binds to specific DNA regulatory elements located 
near target genes (26).  Binding of the hormone:receptor complex influences mRNA 
transcription of the target gene by interacting with basal transcription machinery or through the 
recruitment of other secondary transcription factors (26).  
These observations led us to hypothesize that estrogens may act directly on the HHV8 
genome to alter gene expression.  We therefore sought to identify whether estrogen receptor 
binding sequences exist in the HHV8 genome.  To accomplish this goal, we used a 
computational approach to search the HHV8 genome for sequences with a high degree of 
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similarity to the human estrogen receptor consensus binding sequence.  We further performed a 
functional analysis to determine whether ERE sequences identified in the HHV8 genome were 
able bind estrogen receptor proteins and could modify gene expression in response to treatment 
with estrogens.    
5.2 FINDINGS 
5.2.1 Computational analysis 
Our computational search of the HHV8 genome identified a total of 20 sequences with a high 
degree of similarity to the consensus estrogen response elements sequence.  The cutoff scores for 
our algorithm were set to predict an estimate of 1 false positive for every 10,000 base pairs of 
sequences searched, therefore a total of less than 4.5 false positives was expected.  This 
identification of >4 fold more high scoring sequences than expected indicates that the HHV8 
genome is enriched for ERE-like sequences.   
Of these 20 sequences with similarity to the ERE consensus sequence, 3 were identified 
in a cluster of genes with important regulatory roles in controlling latent/lytic gene expression 
from the HHV8 genome.  An expanded search of this region identified an additional 2 sequences 
inside the ORF50 open reading frame.  This cluster contains 2 genes, ORF49 and ORF50/Rta, 
which are known transcriptional activators of lytic gene expression (158,167).  A third gene 
located within this cluster is the K8 or bZIP gene.  K8 has been shown to act as an inhibitor of 
ORF50 and represses its ability to activate lytic genes (156).  The 2 highest scoring ERE 
sequences identified in our computational analysis were located upstream of the K8 gene, 314bp 
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and 399bp upstream of the ATG in a region previously described to contain transcription factor 
binding sites and act as a distal promoter that controls K8 expression levels (153).   Each of the 3 
genes in this cluster play important regulatory roles in controlling HHV8 gene expression and the 
switch from latency to the lytic phase, therefore we selected ERE-like sequences found in this 
region for further functional analysis. 
An additional ERE chosen for further analysis was located in front of the ORF74 gene.  
ORF74 encodes a G-protein coupled receptor with homology to the human interleukin 8 receptor 
(IL8R) (124).  ORF74 has been shown bind several different cytokines and has a constitutive 
level of signaling that is unaffected by normal IL8R negative feedback pathways  (125).  ORF74 
has also been shown to act as an oncogene that can transform mouse fibroblasts and induce 
tumors in nude mice (126).  In particular endothelial cells expressing ORF74 take on a spindle 
cell-like conformation that resembles the classical cell type observed in KS lesions (127). ORF74 
expression also activates expression of several angiogenic factors such as VEGF (126,168).  The 
clear role of ORF74 in oncogenesis and the morphological changes resulting from its expression 
make it an interesting candidate for further analysis of whether it is a target of estrogen 
regulation. 
5.2.2 Binding experiments 
Electrophoretic mobility shift assay of DNA probes containing the ERE-like sequences found in 
front of the K8, ORF49, and ORF74 genes indicated that each of these candidate sequences were 
bound by proteins from MCF7 nuclear extracts.  NoShift assay further confirmed the protein 
binding to these probes was the estrogen receptor alpha.  Therefore we can conclude that each of 
these 3 ERE-like sequences are bound by the human estrogen receptor alpha.   A similar band 
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shift was observed when nuclear extracts from HCT116 cells was used in gel-shift assays, 
therefore it is likely that both the alpha and beta estrogen receptors bind these sequences.  Cold 
competition assay of our candidate sequences indicated that binding of estrogen receptor to these 
probes was specific and not a result of artifact. 
5.2.3 Reporter assays 
Binding of estrogen receptor proteins to sequences with a high degree of similarity to the 
consensus ERE sequences was largely expected.  However, whether these sequences were 
capable of influencing mRNA expression of a downstream gene was unclear.  Therefore we 
performed a series of reporter assays to further assess whether these sequences were capable of 
acting as true EREs in the context of the full viral gene promoter. 
Results from our luciferase reporter assays indicated that in MCF7 cells expressing the 
ER-alpha protein, treatment with physiologic levels of estradiol resulted in a significantly 
increased expression of a luciferase reporter gene under the control of the K8 promoter 
(p<0.0001).  We observed a greater than 2 fold increase in reporter expression with the full 
length K8 promoter.  Analysis of reporter constructs containing the ORF49 and ORF74 upstream 
regions did not show any significant change in reporter expression when treated with estrogens.  
However, the ORF49 and ORF74 sequences used in our reporter plasmids are 5’-regions 
upstream of the ATG start site and may not necessarily represent a true gene promoter.  In the 
case of the ORF74 gene, the major mRNA species are transcribed as either a bicistronic mRNA 
initiated upstream of the K14 locus or as a monocistronic transcript initiated upstream of our 
ERE sequence.  Therefore, the luciferase reporter plasmid used in our experiments may lack the 
natural promoter elements required for initiating transcription and may be unsuitable for acting 
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as a promoter by itself.  These ERE sequences could still act as an enhancer and could influence 
transcription at true ORF74 promoter in response to estrogens.  Either incorporating a larger 
portion of the 5’-region into our reporter plasmid or examining ORF49 and ORF74 mRNA 
expression in the full context of the virus would be necessary to answer this question. 
Our computational analysis identified 2 high scoring ERE sequences upstream of the K8 
gene, therefore we sought to determine which of these 2 sequences was responsible for the 
observed response to estrogens.  Promoter constructs containing truncated portions of the K8 
promoter were created and transfected into MCF-7 cells.  We observed a similar response to 
estrogens in a construct in which most of the region 5’ of the ERE sequences was removed 
indicating that this upstream flanking region does not appear to be responsible for estrogen 
response.  A dramatic decrease in estrogen response was observed when the region containing 
both ERE sequences was deleted.  Therefore the region containing these ERE sequences is 
essential for response to estrogens.  Deletion of the lower scoring upstream ERE sequence also 
resulted in a loss of estrogen response, indicting that either this ERE or the presence of both ERE 
sequences is necessary for mediating the response to estrogens. 
In order to test whether the ERE sequences identified in front of the K8, ORF49, and 
ORF74 genes could be induced by cell types expressing the beta estrogen receptor, we repeated 
our analysis using several cell types expressing ER-beta.  Both the colon cancer line HCT116 
and CV-1 cells transfected with a ER-beta expression construct were tested, however we did not 
observe significant reporter expression from any of our reporter constructs, including the positive 
control plasmid.  Because of this we were unable to asses whether ER-beta was able to influence 
transcription levels of our reporter plasmid.  
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5.2.4 Estrogen treatment of cells latently infected with HHV8 
EMSA analysis using nuclear extracts isolated from HCT116 cells expressing the beta estrogen 
receptor showed positive band shifts on all of our experimental probes, suggesting binding of 
ERbeta to these ERE sequences.  Therefore we sought to determine if estrogens could influence 
expression of these genes in cells latently infected with HHV8.  For our analysis we used the 
BCBL-1 cell line which is derived from a primary effusion lymphoma.  After treating BCBL-1 
cultures with estrogens, we monitored changes in K8 mRNA levels using Taqman Realtime 
PCR.  Our analysis indicated that K8 mRNA levels did not significantly deviate from levels seen 
in untreated cultures, while TPA strongly induced K8 transcription.  Therefore estrogens do not 
appear to influence K8 levels in BCBL-1 cells.  BCBL-1 cells are believed to have originated 
from a post-germinal center b-cell lineage (169).  B-cell populations are known to express high 
levels of the beta estrogen receptor and comparatively little alpha estrogen receptor (170), 
therefore our findings indicate that estrogen treatment has little effect on K8 mRNA expression 
in cell types expressing the beta estrogen receptor.  Intriguingly a number of cell types found to 
support latent infection of HHV8, such as prostate epithelium (89) and b-cells predominantly 
express the beta estrogen receptor with little or no estrogen receptor alpha expression (170). 
5.2.5 Phylogenetic analysis 
The presence of estrogen response elements and the use of estrogen signaling pathways by a 
diverse variety of viral pathogens led us to speculate whether the presence of estrogen response 
element may be a common to other members of the gammaherpesvirus family.  The presence of 
conserved ERE sequences in other gammaherpesviruses would further confirm that these 
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sequences are an important part of gammaherpesvirus biology.  Therefore we expanded our 
computational analysis to include all other gammaherpesviruses with fully annotated genome 
reference sequences.  Results of our analysis confirmed the presence of ERE sequences in other 
gammaherpesviruses, including the discovery of a fully consensus ERE sequence in the Rhesus 
Rhadinovirus ORF57/Mta promoter.  Our analysis also confirmed that ERE sequences were 
conserved in homologs of the HHV8 K8 and ORF74 genes, although only ORF74 reached 
statistical significance.  However, the presence of 2 ERE sequences in close proximity upstream 
of the HHV8 and EBV bZIP genes suggests that these sequences may play an important role in 
human gammaherpesviruses.  We further found that ERE sequences were highly conserved in 
the upstream region of glycoprotein M homologs in the gammaherpesvirus, though the biological 
significance of this finding is unclear.  Glycoprotein M (gM) encodes a structural protein that 
localizes to the virion (171).  The gM protein is known to complex with gN and has been 
hypothesized to play a role in viral entry and egress (171).  The identification of ERE sequences 
upstream of gM could be confounded by underlying amino acid conservation in the gene located 
upstream, a helicase/primase conserved among the herpesviruses (UL8 homologs).  However the 
position of these EREs in the gammaherpesvirus UL8 homolog proteins is highly variable, 
making that unlikely.  Overall our computational search successfully identified the widespread 
presence of ERE sequences in diverse members of the gammaherpesvirus family.  Therefore 
these results provide strong evidence of a biological importance of EREs in the 
gammaherpesviruses and provide strong corroborating evidence that our initial findings in 
HHV8 are unlikely to be explained by chance alone. 
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5.3 MODEL 
Our findings indicate that the HHV8 genome is enriched for sequences resembling the estrogen 
receptor consensus binding sequence.  We have shown that these sequences are capable of 
binding estrogen receptor proteins in vitro.  Further we have shown that K8 promoter is 
responsive to treatment with estrogens and that the K8 promoter region containing high scoring 
ERE sequences is essential for the response to estrogens.  Our functional analysis has been 
limited to cell types expressing the alpha estrogen receptor, however treatment of BCBL-1 cells 
with estrogens did not appear to have an effect on K8 mRNA levels.  Therefore we conclude that 
estrogens do not appear to directly change K8 mRNA expression in latently infected b-cells, 
which are the primary cell type harboring HHV8 DNA in non-KS individuals.   
Extraneous DNA sequences are unlikely to be maintained in viral genomes due to their 
comparatively rapid rate of genome evolution (172) and the physical constraints imposed on the 
viral genome due to limited the space inside the viral capsid.   Therefore the presence of estrogen 
response elements suggests that these sequences are utilized by the virus.  This role is unlikely to 
involve primary infection, as men and women show similar levels of HHV8 seroprevalence and 
any DNA element that inhibited viral infection would likely be lost rapidly to natural selection.   
However the striking sex bias in the incidence of KS in men and women may be a result 
of the effect of estrogens.  The cell type characteristically seen in KS lesions is the spindle cell 
(95).  Analyses of cell surface markers on HHV8-infected spindle cells indicate that they are of 
an endothelial origin (173), a cell type known to express both the alpha and beta estrogen 
receptors (30), so in women the presence of higher levels of circulating estrogens may act to 
increase K8 expression.  This increased level of K8 expression may have effect on the ability of 
HHV8 to establish an initial latent infection in endothelial cells or may act to suppress local 
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spreading of HHV8 infection to other endothelial cells once an initial endothelial cell is infected 
(Figure 21).  Populations of spindle cells present in early KS lesions are known not to be clonally 
derived therefore KS lesions likely require the infection of significant numbers of endothelial 
cells. Reducing the transfer of HHV8 from b-cell populations to endothelial cells may decrease 
the likelihood of transforming endothelial cells into spindle cells, characteristic of KS.  Therefore 
estrogens may act to reduce the number of endothelial cells infected with HHV8, resulting in the 
decreased KS incidence in women.   
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Figure 21. Model of Estrogen Action on HHV8 Pathogenesis 
Illustration of proposed model of the effect of estrogens on KS progression.  A) HHV8 
establishes an initial primary infection and sets up a latent infection in ERα-/ERβ+ b-cells.   HHV8 is 
then transmitted to ERα+/ERβ+ endothelial cells which then experience a local spreading of virus to 
nearby endothelial cells.  B) Blue arrows indicating points where estrogen activation of K8 could 
repress ORF50 activation and prevent either initial infection of endothelial cells or local spreading. 
 
 
The role of K8 as an inhibitor of ORF50 also suggests that estrogens may act to limit 
reactivation of HHV8-infected b-cells.  In culture, HHV8-infected b-cells exhibit a “leaky” form 
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of latency where a small proportion of cells are undergoing spontaneously reactivation (95).  The 
presence of significant levels of circulating estrogens may act to suppress the ability of these 
cells to reactivate in response to triggers such as TPA or ORF50 expression. 
The presence of a DNA element that acted to suppress viral infection of reactivation 
would generally be selected against by natural selection, as mutant viruses lacking this sequence 
would replicate and spread more effectively than a wildtype virus containing the suppressive 
ERE.  However, if this element was important part of viral biology that gave it a selective 
advantage, the element could be retained through balancing selection.  Widespread viral 
infection to all cell types in the host would likely result in either host death or a massive host 
immune response to viral antigens.  Observations of cell types natural infected by herpesviruses 
include a variety of glandular cells such as prostate (89) and oral epithelia (174).  Infection of 
glandular tissue provides an effective location to allow transmission of virus from an infected 
host by bodily fluids such as saliva and semen. Intriguingly, these cell types express primarily 
the beta estrogen receptor (44,175), as do B-cells (170). Therefore the alpha receptor may act to 
suppress infection in certain cell types in order to limit viral infection to those preferred by the 
virus for efficient spreading.  Therefore limited spreading to preferred cell types would reduce 
the likelihood of triggering an immune response to HHV8 antigens.  Therefore estrogens may 
play a role in viral trophism. 
K8 also has been shown to physically interact with the HHV8 lytic origin of replication 
(157).  Increased levels of K8 expression resulting from estrogens may also influence of the rate 
of HHV8 viral DNA replication.  This proposed role has previously been observed in the 
estrogen response element in the late leader sequence of the BK virus (176).  In the BK virus, 
estrogens were observed to increase the efficiency of viral particle production by increasing the 
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expression of a late structural protein involved in capsid formation (176).  This observation may 
also provide a plausible basis for ERE sequences found upstream of structural proteins in the 
HHV8 genome and may warrant further investigation of these genes. 
5.4 ROLE OF HHV8 IN PROSTATE CANCER 
The results of our functional analysis failed to identify estrogen regulation of any HHV8 genes 
with known oncogenic potential, such as ORF74.  However, the low levels of estrogens in men 
would reduce the activation of K8 which would likely ease repression of ORF50.  This 
mechanism may allow local spreading of HHV8 into the prostate.  The establishment of a 
chronic infection in the prostate by HHV8 could trigger inflammatory responses which have 
been proposed to be a critical part of prostate cancer pathogenesis (177). 
Further, our functional analysis has been limited to a small subset of candidate ERE 
sequences identified in the HHV8 genome.  At least 15 other HHV8 genes are potential targets 
of estrogen regulation which remain untested.  Further analysis of these genes as targets of 
estrogen regulation may reveal the involvement of other HHV8 genes in KS or prostate cancer 
pathogenesis. 
While our findings provide a mechanism linking the estrogen receptor alpha to prostate 
cancer, the role of the XbaI polymorphism is unclear.  Despite its association with a variety of 
estrogen-related diseases, to date no functional role has been attributed to this variant.  Linkage 
to other variants with true functional roles could explain its effect on prostate cancer.  One caveat 
of our analysis is that use of odds ratios when assessing interaction between common factors 
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could result in an inflated estimate of the true risk ratios (178).  This effect could be reduced by 
the use of relative risks, however the case-control nature of our study prevents that.   
5.5 EXAMPLES OF VIRAL INTERACTION WITH HORMONES IN THE 
LITERATURE 
Various examples of interaction between viruses and steroid hormones have previously been 
reported and provide evidence that this interaction may be a commonly utilized pathway.  One of 
the earliest characterized hormone response elements was found in the Mouse Mammary Tumor 
Virus (MMTV).  Archer et al reported the presence of a functional glutocorticoid response 
element (GRE) in the MMTV genome which mediated a strong increase in MMTV RNA 
transcription when infected cells were treated with glucocorticoids such as dexamethasone and 
hydrocortisone (179).  
More recently, several reports have found interactions between the estrogen receptor and 
hepatitis viruses.  Deng et al reported individuals infected with hepatitis B virus (HBV) who 
carried the estrogen receptor PvuII polymorphism were at an increased risk of chronic HBV 
infection (180) and Zhai et al reported a similar interaction associated with risk of hepatocellular 
carcinoma (181).  This association was found to have a plausible biological basis when the 
human estrogen receptor alpha was shown to physically interact with the hepatitis C virus (HCV) 
RNA polymerase protein NS5B (182).  It was further reported that the estrogen antagonist 
tamoxifen was able to suppress HCV genome replication (182).    
These examples clearly show the widespread utilization of estrogen signaling pathways 
by evolutionarily unrelated viruses in which each virus has co-opted the pathway for its own 
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uses.  In many cases this interaction is limited to physical binding of viral proteins to the 
estrogen receptor, however classical estrogen signaling pathways involving the presence of ERE 
sequences upstream of viral genes have also been described as well.  An example of this is the 
ERE described in the late leader region of the BK virus (176).  
 While the incidence of KS in women is known to be exceedingly rare, cases of HIV- 
women diagnosed with KS have been reported.  This observation leads us to question what 
factors contribute to KS progression in this small minority of women. In an intriguing report by 
Schofer et al, they found that in a small sample of 7 women diagnosed with KS (4 HIV+; 3 HIV-
), all 7 had abnormally low serum estradiol levels compared to controls (183).  While a small 
sample size precluded these findings from reaching significance, these results provide tantalizing 
evidence for a protective effect of estrogens in KS progression. 
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6.0  CONCLUSION 
Our analysis of the HHV8 genome has revealed the presence of several sequences that highly 
resemble the consensus estrogen receptor binding sequence.  We have shown that ERE-like 
sequences located in front of the K8, ORF49 and ORF74 genes are capable of binding estrogen 
receptor proteins.  Further our analysis indicates that the K8 promoter is responsive to 
physiologic levels of estrogen and that this response is carried out by a segment of the K8 
promoter containing the 2 highest scoring sequences in our analysis.  We therefore conclude that 
in cell types expressing estrogen receptor alpha, that estrogens regulate K8 expression outside of 
the normal viral program.  These findings may provide a mechanism to explain the observed sex-
bias in KS incidence and provide a plausible biologic foundation for the interaction of estrogen 
receptor polymorphisms with HHV8 seropositivity in the risk of prostate cancer.  We have also 
expanded our analysis and discovered the presence of ERE-like sequences in other members of 
the gammaherpesvirus family, suggesting that this signaling pathway may be utilized by other 
evolutionarily related viruses. 
Here we describe potential insights into the pathobiology of two human neoplasias, 
prostate cancer and Kaposi’s sarcoma.  Both of these diseases have significant impacts on public 
health in the United States and world-wide.  In the United States, prostate cancer is the most 
commonly diagnosed non-skin related cancer and the second leading cause of cancer-related 
mortality in men.  While Kaposi’s sarcoma is rarely observed in healthy individuals, it is a 
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common occurrence in HIV positive men and has a much higher incidence in Mediterranean 
areas and in parts of sub-Saharan Africa.  We believe our findings may provide insights into the 
underlying biology of Kaposi’s sarcoma and may help to explain the increased incidence of 
prostate cancer observed in Tobago.     
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